This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-125b-5p | AIFM1 | 0.04 | 0.98059 | -0.13 | 0.93316 | miRNATAP | -0.07 | 0.04571 | NA | |
2 | hsa-miR-125b-5p | AKT1 | 0.04 | 0.98059 | -0.06 | 0.97402 | miRNAWalker2 validate; miRTarBase | -0.06 | 0.00668 | NA | |
3 | hsa-miR-106a-5p | AKT3 | -0.2 | 0.80221 | 0.46 | 0.53933 | miRNATAP | -0.55 | 0 | NA | |
4 | hsa-miR-106b-5p | AKT3 | -0.3 | 0.86929 | 0.46 | 0.53933 | miRNATAP | -0.91 | 0 | NA | |
5 | hsa-miR-107 | AKT3 | -0.04 | 0.98836 | 0.46 | 0.53933 | PITA; miRanda | -0.55 | 0.00017 | NA | |
6 | hsa-miR-1275 | AKT3 | -0.83 | 0.08038 | 0.46 | 0.53933 | PITA | -0.27 | 0 | NA | |
7 | hsa-miR-140-5p | AKT3 | -0.23 | 0.84733 | 0.46 | 0.53933 | miRanda | -0.29 | 0.02297 | NA | |
8 | hsa-miR-142-3p | AKT3 | -0.15 | 0.9461 | 0.46 | 0.53933 | miRanda | -0.2 | 0.00627 | NA | |
9 | hsa-miR-15a-5p | AKT3 | -0.07 | 0.96484 | 0.46 | 0.53933 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.72 | 0 | NA | |
10 | hsa-miR-15b-5p | AKT3 | -0.27 | 0.87097 | 0.46 | 0.53933 | miRNATAP | -0.67 | 0 | NA | |
11 | hsa-miR-16-5p | AKT3 | 0.01 | 0.99448 | 0.46 | 0.53933 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.75 | 0 | NA | |
12 | hsa-miR-17-3p | AKT3 | 0.1 | 0.96011 | 0.46 | 0.53933 | miRNATAP | -0.52 | 0 | NA | |
13 | hsa-miR-17-5p | AKT3 | -0.18 | 0.93454 | 0.46 | 0.53933 | TargetScan; miRNATAP | -0.63 | 0 | NA | |
14 | hsa-miR-181b-5p | AKT3 | 0.16 | 0.93018 | 0.46 | 0.53933 | miRNATAP | -0.27 | 0.00963 | NA | |
15 | hsa-miR-20a-5p | AKT3 | -0.18 | 0.92812 | 0.46 | 0.53933 | miRNATAP | -0.53 | 0 | NA | |
16 | hsa-miR-28-3p | AKT3 | -0.23 | 0.93535 | 0.46 | 0.53933 | miRNATAP | -0.52 | 0.00719 | NA | |
17 | hsa-miR-29a-3p | AKT3 | 0.01 | 0.99698 | 0.46 | 0.53933 | miRNATAP | -0.81 | 0 | NA | |
18 | hsa-miR-29b-3p | AKT3 | -0.1 | 0.95899 | 0.46 | 0.53933 | miRNATAP | -0.68 | 0 | 26512921 | MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3 |
19 | hsa-miR-32-3p | AKT3 | -0.57 | 0.13133 | 0.46 | 0.53933 | mirMAP | -0.56 | 0 | NA | |
20 | hsa-miR-320a | AKT3 | -0.42 | 0.8402 | 0.46 | 0.53933 | PITA; miRanda; miRNATAP | -0.33 | 0.00138 | NA | |
21 | hsa-miR-320b | AKT3 | -0.24 | 0.85922 | 0.46 | 0.53933 | PITA; miRanda; miRNATAP | -0.25 | 0.00855 | NA | |
22 | hsa-miR-320c | AKT3 | -0.58 | 0.1136 | 0.46 | 0.53933 | PITA; miRanda; miRNATAP | -0.17 | 0.01525 | NA | |
23 | hsa-miR-335-3p | AKT3 | -0.24 | 0.8845 | 0.46 | 0.53933 | mirMAP | -0.58 | 0 | NA | |
24 | hsa-miR-33a-3p | AKT3 | -0.79 | 0.01052 | 0.46 | 0.53933 | mirMAP | -0.49 | 0 | NA | |
25 | hsa-miR-340-5p | AKT3 | -0 | 0.99757 | 0.46 | 0.53933 | mirMAP | -0.28 | 0.006 | NA | |
26 | hsa-miR-362-3p | AKT3 | -0.72 | 0.03459 | 0.46 | 0.53933 | miRanda | -0.42 | 0 | NA | |
27 | hsa-miR-362-5p | AKT3 | -0.27 | 0.75202 | 0.46 | 0.53933 | PITA; TargetScan; miRNATAP | -0.52 | 0 | NA | |
28 | hsa-miR-369-3p | AKT3 | 0.12 | 0.8323 | 0.46 | 0.53933 | mirMAP | -0.23 | 0.00901 | NA | |
29 | hsa-miR-374a-5p | AKT3 | -0.34 | 0.76692 | 0.46 | 0.53933 | mirMAP | -0.58 | 0 | NA | |
30 | hsa-miR-374b-5p | AKT3 | -0.29 | 0.8357 | 0.46 | 0.53933 | mirMAP | -0.68 | 0 | NA | |
31 | hsa-miR-421 | AKT3 | -0.18 | 0.7347 | 0.46 | 0.53933 | miRanda; mirMAP | -0.46 | 0 | NA | |
32 | hsa-miR-424-5p | AKT3 | 0.25 | 0.87015 | 0.46 | 0.53933 | miRNATAP | -0.24 | 0.00104 | 26315541 | Silencing Akt3 and E2F3 by siRNA pheno-copied the effect of ectopic miR-424 on HCC growth; Whereas overexpression of Akt3 and E2F3 attenuated the effect of miR-424 on HCC growth |
33 | hsa-miR-501-3p | AKT3 | -0.75 | 0.55276 | 0.46 | 0.53933 | miRNATAP | -0.5 | 0 | NA | |
34 | hsa-miR-502-3p | AKT3 | -0.48 | 0.5143 | 0.46 | 0.53933 | miRNATAP | -0.64 | 0 | NA | |
35 | hsa-miR-502-5p | AKT3 | -0.71 | 0.02613 | 0.46 | 0.53933 | PITA; miRNATAP | -0.41 | 0 | NA | |
36 | hsa-miR-505-3p | AKT3 | -0.47 | 0.69038 | 0.46 | 0.53933 | mirMAP | -0.77 | 0 | 22051041 | We also find that Akt3 correlate inversely with miR-505 modulates drug sensitivity in MCF7-ADR |
37 | hsa-miR-539-5p | AKT3 | 0.12 | 0.80107 | 0.46 | 0.53933 | mirMAP; miRNATAP | -0.19 | 0.0467 | NA | |
38 | hsa-miR-548o-3p | AKT3 | -0.19 | 0.51773 | 0.46 | 0.53933 | mirMAP | -0.31 | 8.0E-5 | NA | |
39 | hsa-miR-577 | AKT3 | -1.06 | 0.32606 | 0.46 | 0.53933 | mirMAP | -0.38 | 0 | NA | |
40 | hsa-miR-663b | AKT3 | 0.1 | 0.81499 | 0.46 | 0.53933 | PITA | -0.25 | 1.0E-5 | NA | |
41 | hsa-miR-769-5p | AKT3 | -0.31 | 0.7357 | 0.46 | 0.53933 | PITA; miRNATAP | -0.84 | 0 | NA | |
42 | hsa-miR-93-5p | AKT3 | -0.61 | 0.8253 | 0.46 | 0.53933 | miRNATAP | -0.76 | 0 | NA | |
43 | hsa-miR-708-3p | APAF1 | 0.14 | 0.89698 | -0.17 | 0.88665 | mirMAP | -0.11 | 0.0011 | NA | |
44 | hsa-miR-146b-5p | ATM | -0.4 | 0.83751 | 0.19 | 0.86463 | miRanda | -0.09 | 0.03968 | 27602131 | The role of microRNA 146b miR-146b in ATC remains to be elucidated; In order to characterize the role of miR-146b in ATC overexpression or interference of miR-146b was induced in ATC cell lines and cell proliferation and migration were evaluated; The potential targets of miR-146b were searched in the Gene Expression Omnibus database for ATC and matched non-tumor control samples; The expression level of potential targets was detected following overexpression or interference of miR-146b in ATC cell lines; In addition cell migration of ATC was also affected by miR-146b; During the search for potential targets of miR-146b in ATC p21 also known as p21Waf1/Cip1 or CDKN1A was noted for its role in cell cycle progression and tumor pathogenesis; In conclusion p21 may participate in the regulation of ATC cell proliferation by miR-146b |
45 | hsa-miR-18a-5p | ATM | -0.5 | 0.61264 | 0.19 | 0.86463 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.07 | 0.00927 | 23229340; 23437304; 25963391; 23857602 | MicroRNA 18a upregulates autophagy and ataxia telangiectasia mutated gene expression in HCT116 colon cancer cells; Previous studies showed that certain microRNAs including miR-18a potentially regulate ATM in cancer cells; However the mechanisms behind the modulation of ATM by miR-18a remain to be elucidated in colon cancer cells; In the present study we explored the impact of miR-18a on the autophagy process and ATM expression in HCT116 colon cancer cells; Western blotting and luciferase assays were implemented to explore the impact of miR-18a on ATM gene expression in HCT116 cells; Moreover miR-18a overexpression led to the upregulation of ATM expression and suppression of mTORC1 activity; Results of the present study pertaining to the role of miR-18a in regulating autophagy and ATM gene expression in colon cancer cells revealed a novel function for miR-18a in a critical cellular event and on a crucial gene with significant impacts in cancer development progression treatment and in other diseases;MicroRNA 18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer; Through in silico search the 3'UTR of Ataxia telangiectasia mutated ATM contains a conserved miR-18a binding site; Expression of ATM was down-regulated in CRC tumors p<0.0001 and inversely correlated with miR-18a expression r = -0.4562 p<0.01; This was further confirmed by the down-regulation of ATM protein by miR-18a; As ATM is a key enzyme in DNA damage repair we evaluated the effect of miR-18a on DNA double-strand breaks; miR-18a attenuates cellular repair of DNA double-strand breaks by directly suppressing ATM a key enzyme in DNA damage repair;However the upregulation of miR-18a suppressed the level of ataxia-telangiectasia mutated and attenuated DNA double-strand break repair after irradiation which re-sensitized the cervical cancer cells to radiotherapy by promoting apoptosis;Furthermore we used antisense oligonucleotides against micro RNAs miRNA or miRNA overexpression plasmids to study the role of miR-18a and -106a on ATM expression; Furthermore we identified that ERα activates miR-18a and -106a to downregulate ATM expression; We reveal a novel mechanism involving ERα and miR-18a and -106a regulation of ATM in breast cancer |
46 | hsa-miR-21-5p | ATM | -0.15 | 0.97024 | 0.19 | 0.86463 | mirMAP | -0.12 | 0.04916 | 26289851 | MiR-21 is an oncomiR that is overexpressed in nearly all cancers including ATC; Hence suppression of miR-21 could pave the way for ATC therapy |
47 | hsa-miR-26b-5p | ATM | -0.02 | 0.99038 | 0.19 | 0.86463 | MirTarget | -0.1 | 0.03639 | NA | |
48 | hsa-miR-29a-5p | ATM | -0.32 | 0.60044 | 0.19 | 0.86463 | mirMAP | -0.08 | 0.01391 | NA | |
49 | hsa-miR-324-5p | ATM | -0.5 | 0.53742 | 0.19 | 0.86463 | miRanda | -0.12 | 0.00155 | NA | |
50 | hsa-miR-339-5p | ATM | -0.3 | 0.71291 | 0.19 | 0.86463 | miRanda | -0.07 | 0.02232 | NA | |
51 | hsa-miR-362-3p | ATM | -0.72 | 0.03459 | 0.19 | 0.86463 | miRanda | -0.07 | 0.02113 | NA | |
52 | hsa-miR-455-5p | ATM | -0.14 | 0.86574 | 0.19 | 0.86463 | miRanda | -0.12 | 0.00128 | NA | |
53 | hsa-miR-576-5p | ATM | -0.51 | 0.41719 | 0.19 | 0.86463 | mirMAP | -0.09 | 0.01709 | NA | |
54 | hsa-miR-577 | ATM | -1.06 | 0.32606 | 0.19 | 0.86463 | PITA | -0.06 | 0.00179 | NA | |
55 | hsa-miR-590-3p | ATM | -0.28 | 0.59127 | 0.19 | 0.86463 | miRanda; mirMAP | -0.06 | 0.03618 | NA | |
56 | hsa-miR-590-5p | ATM | -0.55 | 0.47274 | 0.19 | 0.86463 | mirMAP | -0.1 | 0.00142 | NA | |
57 | hsa-miR-129-5p | BAD | 0.27 | 0.55335 | 0.1 | 0.93266 | miRanda | -0.07 | 0.00168 | NA | |
58 | hsa-miR-153-3p | BCL2 | -0.5 | 0.30683 | -0.87 | 0.24496 | miRNAWalker2 validate; miRTarBase | -0.12 | 0.0323 | 19676043; 21213215 | Bioinformatics analysis revealed that anti-apoptosis family member B-cell lymphoma 2 Bcl-2 and myeloid cell leukemia sequence 1 Mcl-1 are potential targets of miR-153; Indeed Western blot analysis indicated that miR-153 downregulated both Bcl-2 and Mcl-1 at the protein levels; By luciferase reporter assays we further showed that miR-153 inhibited Bcl-2 and Mcl-1 expressions by directly targeting the 3'UTR regions of their respective mRNAs;Previously we established that microRNA-153 miR-153 induces apoptosis by downregulating B-cell lymphoma 2 Bcl-2 and myeloid cell leukemia sequence 1 Mcl-1 protein expression levels in glioblastoma cell line DBTRG-05MG |
59 | hsa-miR-15a-5p | BCL2 | -0.07 | 0.96484 | -0.87 | 0.24496 | miRNAWalker2 validate; miRTarBase | -0.22 | 0.02911 | 25623762; 25594541; 26915294; 18931683; 22335947 | miR 15a and miR 16 modulate drug resistance by targeting bcl 2 in human colon cancer cells; To investigate the reversal effect of targeted modulation of bcl-2 expression by miR-15a and miR-16 on drug resistance of human colon cancer cells;MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MicroRNAs miRNAs are noncoding small RNAs that repress protein translation by targeting specific messenger RNAs miR-15a and miR-16-1 act as putative tumor suppressors by targeting the oncogene BCL2;The expression of MiR-15a was significantly inhibited by Bcl-2 P < 0.05 |
60 | hsa-miR-16-5p | BCL2 | 0.01 | 0.99448 | -0.87 | 0.24496 | miRNAWalker2 validate; miRTarBase | -0.23 | 0.01553 | 25623762; 21336967; 24447552; 18449891; 25435430; 24598659; 18931683; 22966344 | miR 15a and miR 16 modulate drug resistance by targeting bcl 2 in human colon cancer cells; To investigate the reversal effect of targeted modulation of bcl-2 expression by miR-15a and miR-16 on drug resistance of human colon cancer cells;P glycoprotein enhances radiation induced apoptotic cell death through the regulation of miR 16 and Bcl 2 expressions in hepatocellular carcinoma cells; RHepG2 cells the multidrug resistant subline of human hepatocellular carcinoma HepG2 cells expressed higher levels of Pgp as well as miR-16 and lower level of Bcl-2 than the parental cells; On the other hand ectopic mdr1 expression enhanced radiation-induced apoptosis in HepG2 cells SK-HEP-1 cells MiHa cells and furthermore induced miR-16 and suppressed its target gene Bcl-2 in HepG2 cells; Moreover the enhancement effects of Pgp and miR-16 on radiation-induced apoptosis were counteracted by overexpression of Bcl-2;To study the expression of miR-16 and bcl-2 in T lymphoblastic lymphoma/leukemia T-LBL/ALL and its relationship to prognosis; The relationship of miR-16 and bcl-2 was significantP = 0.042χ2 = 4.147; The relationship of miR-16 and bcl-2 might suggested that gene regulation may be influenced by them;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2;We demonstrated that anti-apoptotic protein Bcl-2 was directly targeted miR-16 in paclitaxel resistant lung cancer cells; Combined overexpression of miR-16 and miR-17 greatly reduced Beclin-1 and Bcl-2 expressions respectively; miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1 whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2;The miR-16 expression correlated with BCL-2 protein r = 0.51 P < 0.05;MicroRNAs miRNAs are noncoding small RNAs that repress protein translation by targeting specific messenger RNAs miR-15a and miR-16-1 act as putative tumor suppressors by targeting the oncogene BCL2;The overall objective of our investigation was to assess whether miRNA-16 miR-16 is involved in the regulation of critical genes such as BCL2 that control the sensitivity of pancreatic cancer cells to apoptosis; This study showed that the ectopic overexpression of miR-16 may be therapeutically beneficial as is evidenced by impaired cell survival with concomitant attenuation of anti-apoptotic protein Bcl-2; Moreover the luciferase reporter assay suggested that miR-16 post-transcriptionally regulates Bcl-2 expression in pancreatic cancer cells through the target sites of the 3' untranslated region of this gene |
61 | hsa-miR-17-5p | BCL2 | -0.18 | 0.93454 | -0.87 | 0.24496 | miRNAWalker2 validate; miRTarBase | -0.31 | 2.0E-5 | 25435430 | Combined overexpression of miR-16 and miR-17 greatly reduced Beclin-1 and Bcl-2 expressions respectively; miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1 whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2 |
62 | hsa-miR-192-5p | BCL2 | -0.12 | 0.97293 | -0.87 | 0.24496 | miRNAWalker2 validate | -0.23 | 0.00056 | 26550150 | MicroRNA 192 regulates chemo resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl 2; In this paper we try to test whether miR-192 regulates chemo-resistance in human carcinoma A549 mice model by targeting Bcl-2; MTT assay real-time RT-PCR western blotting assay were used to investigate miR-192 expression levels cell viability ratio and Bcl-2 protein expression levels; Bcl-2 mRNA and protein expression levels up-regulated in miR-192 inhibitor treated tumor; Bcl-2 is a key regulator for miR-192 related chemotherapy resistance; In this study we demonstrate that miR-192 regulates chemoresistance for gemcitabine and cisplatin combined chemotherapy in human adenocarcinoma lung cancer A549 cells and Bcl-2 is the target of miR-192 |
63 | hsa-miR-196b-5p | BCL2 | -0.08 | 0.97211 | -0.87 | 0.24496 | miRNAWalker2 validate | -0.13 | 0.00926 | NA | |
64 | hsa-miR-20a-3p | BCL2 | 0.46 | 0.57674 | -0.87 | 0.24496 | mirMAP | -0.19 | 0.00115 | NA | |
65 | hsa-miR-20a-5p | BCL2 | -0.18 | 0.92812 | -0.87 | 0.24496 | miRNAWalker2 validate; miRTarBase | -0.25 | 0.00046 | NA | |
66 | hsa-miR-224-3p | BCL2 | 0.11 | 0.74909 | -0.87 | 0.24496 | mirMAP | -0.18 | 0.00775 | 24796455 | In addition the expressions of Bcl2 mRNA and protein were 1.05 ± 0.04 and 0.21 ± 0.03 in the miR-224 ASO group significantly lower than that in the control group 4.87 ± 0.96 and 0.88 ± 0.09 P < 0.01 |
67 | hsa-miR-224-5p | BCL2 | -0.24 | 0.85735 | -0.87 | 0.24496 | mirMAP | -0.3 | 0 | 24796455 | In addition the expressions of Bcl2 mRNA and protein were 1.05 ± 0.04 and 0.21 ± 0.03 in the miR-224 ASO group significantly lower than that in the control group 4.87 ± 0.96 and 0.88 ± 0.09 P < 0.01 |
68 | hsa-miR-24-2-5p | BCL2 | -0.09 | 0.92016 | -0.87 | 0.24496 | miRNAWalker2 validate; miRTarBase | -0.41 | 0.00012 | NA | |
69 | hsa-miR-29a-3p | BCL2 | 0.01 | 0.99698 | -0.87 | 0.24496 | miRNAWalker2 validate; miRTarBase | -0.34 | 0.00194 | 20041405 | Subsequent investigation characterized two antiapoptotic molecules Bcl-2 and Mcl-1 as direct targets of miR-29; Furthermore silencing of Bcl-2 and Mcl-1 phenocopied the proapoptotic effect of miR-29 whereas overexpression of these proteins attenuated the effect of miR-29 |
70 | hsa-miR-29a-5p | BCL2 | -0.32 | 0.60044 | -0.87 | 0.24496 | mirMAP | -0.34 | 1.0E-5 | 20041405 | Subsequent investigation characterized two antiapoptotic molecules Bcl-2 and Mcl-1 as direct targets of miR-29; Furthermore silencing of Bcl-2 and Mcl-1 phenocopied the proapoptotic effect of miR-29 whereas overexpression of these proteins attenuated the effect of miR-29 |
71 | hsa-miR-29b-3p | BCL2 | -0.1 | 0.95899 | -0.87 | 0.24496 | miRNAWalker2 validate; miRTarBase | -0.27 | 0.00119 | 20041405 | Subsequent investigation characterized two antiapoptotic molecules Bcl-2 and Mcl-1 as direct targets of miR-29; Furthermore silencing of Bcl-2 and Mcl-1 phenocopied the proapoptotic effect of miR-29 whereas overexpression of these proteins attenuated the effect of miR-29 |
72 | hsa-miR-335-3p | BCL2 | -0.24 | 0.8845 | -0.87 | 0.24496 | mirMAP | -0.25 | 0.00118 | NA | |
73 | hsa-miR-33a-5p | BCL2 | -0.21 | 0.85331 | -0.87 | 0.24496 | mirMAP | -0.13 | 0.00456 | NA | |
74 | hsa-miR-374b-5p | BCL2 | -0.29 | 0.8357 | -0.87 | 0.24496 | mirMAP | -0.29 | 0.0137 | NA | |
75 | hsa-miR-450b-5p | BCL2 | -0.01 | 0.98315 | -0.87 | 0.24496 | mirMAP | -0.24 | 0.00586 | NA | |
76 | hsa-miR-452-5p | BCL2 | -0.05 | 0.97387 | -0.87 | 0.24496 | mirMAP | -0.28 | 0.00061 | NA | |
77 | hsa-miR-590-5p | BCL2 | -0.55 | 0.47274 | -0.87 | 0.24496 | miRanda | -0.18 | 0.01554 | NA | |
78 | hsa-miR-7-5p | BCL2 | 0.21 | 0.77371 | -0.87 | 0.24496 | miRNAWalker2 validate; miRTarBase; mirMAP | -0.2 | 0.00018 | 26464649; 25862909; 21750649 | Western blotting was used to evaluate the effect of miR-7 on Bcl2 in A549 and H460 cells; Moreover subsequent experiments showed that BCL-2 was downregulated by miR-7 at both transcriptional and translational levels; This study further extends the biological role of miR-7 in NSCLC A549 and H460 cells and identifies BCL-2 as a novel target possibly involved in miR-7-mediated growth suppression and apoptosis induction of NSCLC cells;miR-7 overexpression correlated with diminished BCL2 expression but there was no relationship between miR-7 and EGFR expression neither in tumour samples nor in the cell lines; Of the two postulated miR-7 target genes we examined BCL2 but not EGFR seems to be a possible miR-7 target in OC;Bioinformatics predictions revealed a potential binding site of miR-7 on 3'UTR of BCL-2 and it was further confirmed by luciferase assay; Moreover subsequent experiments showed that BCL-2 was downregulated by miR-7 at both transcriptional and translational levels; These results suggest that miR-7 regulates the expression of BCL-2 through direct 3'UTR interactions |
79 | hsa-let-7a-5p | BCL2L1 | -0.06 | 0.98501 | 0.24 | 0.89096 | TargetScan; miRNATAP | -0.27 | 0.0015 | 26915294; 20347499 | As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;The let 7 family of microRNAs inhibits Bcl xL expression and potentiates sorafenib induced apoptosis in human hepatocellular carcinoma; The effect of let-7 on Bcl-xL expression was examined by Western blot and a reporter assay; Microarray analysis followed by in silico target prediction identified let-7 microRNAs as being downregulated in Huh7 hepatoma cells in comparison with primary human hepatocytes as well as possessing a putative target site in the bcl-xl mRNA |
80 | hsa-miR-326 | BCL2L1 | -0.57 | 0.6207 | 0.24 | 0.89096 | PITA; miRanda; mirMAP; miRNATAP | -0.1 | 0.03992 | NA | |
81 | hsa-miR-511-5p | BID | -0.31 | 0.6072 | -0.06 | 0.96523 | MirTarget | -0.09 | 0.00371 | NA | |
82 | hsa-miR-126-5p | BIRC2 | 0.08 | 0.95664 | -0.01 | 0.9934 | mirMAP | -0.12 | 0.00073 | NA | |
83 | hsa-miR-29b-3p | BIRC2 | -0.1 | 0.95899 | -0.01 | 0.9934 | MirTarget | -0.07 | 0.01456 | NA | |
84 | hsa-miR-421 | BIRC2 | -0.18 | 0.7347 | -0.01 | 0.9934 | miRanda | -0.05 | 0.03914 | NA | |
85 | hsa-miR-500a-5p | BIRC2 | -0.72 | 0.18807 | -0.01 | 0.9934 | MirTarget | -0.07 | 0.00207 | NA | |
86 | hsa-miR-24-1-5p | BIRC3 | -0.19 | 0.79153 | -0.14 | 0.89724 | MirTarget | -0.31 | 0.00145 | NA | |
87 | hsa-miR-24-2-5p | BIRC3 | -0.09 | 0.92016 | -0.14 | 0.89724 | MirTarget | -0.21 | 0.0414 | NA | |
88 | hsa-miR-374a-5p | BIRC3 | -0.34 | 0.76692 | -0.14 | 0.89724 | mirMAP | -0.23 | 0.04767 | NA | |
89 | hsa-miR-374b-5p | BIRC3 | -0.29 | 0.8357 | -0.14 | 0.89724 | mirMAP | -0.28 | 0.01092 | NA | |
90 | hsa-miR-651-5p | BIRC3 | -0.57 | 0.17254 | -0.14 | 0.89724 | MirTarget | -0.16 | 0.00706 | NA | |
91 | hsa-miR-20a-3p | CAPN2 | 0.46 | 0.57674 | 0.04 | 0.98149 | MirTarget | -0.11 | 0.00146 | NA | |
92 | hsa-miR-421 | CAPN2 | -0.18 | 0.7347 | 0.04 | 0.98149 | miRanda | -0.25 | 0 | NA | |
93 | hsa-miR-7-5p | CAPN2 | 0.21 | 0.77371 | 0.04 | 0.98149 | miRNAWalker2 validate | -0.12 | 0.0001 | NA | |
94 | hsa-miR-125b-5p | CASP10 | 0.04 | 0.98059 | -0.29 | 0.80713 | mirMAP | -0.09 | 0.02233 | NA | |
95 | hsa-miR-129-5p | CASP10 | 0.27 | 0.55335 | -0.29 | 0.80713 | mirMAP | -0.07 | 0.04141 | NA | |
96 | hsa-miR-145-3p | CASP10 | 0.13 | 0.91316 | -0.29 | 0.80713 | mirMAP | -0.13 | 0.02504 | NA | |
97 | hsa-miR-181c-5p | CASP10 | 0.04 | 0.96916 | -0.29 | 0.80713 | mirMAP | -0.15 | 0.00318 | NA | |
98 | hsa-miR-217 | CASP10 | 0.34 | 0.761 | -0.29 | 0.80713 | mirMAP | -0.08 | 0.04379 | NA | |
99 | hsa-miR-592 | CASP10 | -0.18 | 0.85623 | -0.29 | 0.80713 | miRNATAP | -0.06 | 0.00746 | NA | |
100 | hsa-let-7c-5p | CASP3 | -0.06 | 0.9749 | -0.16 | 0.90316 | MirTarget | -0.09 | 0.00056 | NA | |
101 | hsa-miR-129-5p | CASP3 | 0.27 | 0.55335 | -0.16 | 0.90316 | mirMAP | -0.06 | 0.01293 | 23744359 | The intrinsic apoptotic pathway triggered by miR-129 was activated by cleavage of caspase-9 and caspase-3 |
102 | hsa-miR-139-5p | CASP3 | -0.08 | 0.92869 | -0.16 | 0.90316 | miRanda | -0.08 | 0.02481 | NA | |
103 | hsa-miR-195-3p | CASP3 | 0.12 | 0.69192 | -0.16 | 0.90316 | MirTarget | -0.06 | 0.03633 | NA | |
104 | hsa-miR-30a-5p | CASP3 | 0.22 | 0.93395 | -0.16 | 0.90316 | miRNATAP | -0.2 | 6.0E-5 | NA | |
105 | hsa-miR-125a-3p | CASP6 | 0.15 | 0.72476 | -0.2 | 0.87497 | miRanda | -0.08 | 0.01942 | NA | |
106 | hsa-miR-125a-5p | CASP6 | -0 | 0.99916 | -0.2 | 0.87497 | miRanda | -0.13 | 0.02252 | NA | |
107 | hsa-miR-129-5p | CASP8 | 0.27 | 0.55335 | -0.27 | 0.82859 | miRanda | -0.05 | 0.00484 | NA | |
108 | hsa-miR-143-3p | CASP8 | 0.37 | 0.92734 | -0.27 | 0.82859 | MirTarget | -0.11 | 0.00055 | NA | |
109 | hsa-miR-130b-3p | CFLAR | -0.22 | 0.82466 | -0.06 | 0.9614 | mirMAP | -0.17 | 0 | NA | |
110 | hsa-miR-15b-5p | CFLAR | -0.27 | 0.87097 | -0.06 | 0.9614 | mirMAP | -0.09 | 0.00996 | NA | |
111 | hsa-miR-16-5p | CFLAR | 0.01 | 0.99448 | -0.06 | 0.9614 | mirMAP | -0.08 | 0.02227 | NA | |
112 | hsa-miR-2110 | CFLAR | -0.32 | 0.25098 | -0.06 | 0.9614 | MirTarget | -0.06 | 0.03576 | NA | |
113 | hsa-miR-301a-3p | CFLAR | -0.11 | 0.83169 | -0.06 | 0.9614 | mirMAP | -0.1 | 0.00032 | NA | |
114 | hsa-miR-30c-1-3p | CFLAR | -0.2 | 0.51149 | -0.06 | 0.9614 | mirMAP | -0.08 | 0.00392 | NA | |
115 | hsa-miR-339-5p | CFLAR | -0.3 | 0.71291 | -0.06 | 0.9614 | miRanda | -0.08 | 0.00348 | NA | |
116 | hsa-miR-374a-5p | CFLAR | -0.34 | 0.76692 | -0.06 | 0.9614 | MirTarget | -0.1 | 0.02281 | NA | |
117 | hsa-miR-374b-5p | CFLAR | -0.29 | 0.8357 | -0.06 | 0.9614 | MirTarget | -0.16 | 0.00035 | NA | |
118 | hsa-miR-421 | CFLAR | -0.18 | 0.7347 | -0.06 | 0.9614 | miRanda | -0.11 | 0.00016 | NA | |
119 | hsa-miR-454-3p | CFLAR | -0.1 | 0.84355 | -0.06 | 0.9614 | mirMAP | -0.1 | 0.0097 | NA | |
120 | hsa-miR-484 | CFLAR | -0.18 | 0.88633 | -0.06 | 0.9614 | mirMAP | -0.1 | 0.01431 | NA | |
121 | hsa-miR-660-5p | CFLAR | -0.48 | 0.69408 | -0.06 | 0.9614 | mirMAP | -0.08 | 0.01416 | NA | |
122 | hsa-miR-1254 | CHP2 | -0.49 | 0.19552 | 1.47 | 0.1548 | miRNATAP | -0.41 | 0.02445 | NA | |
123 | hsa-miR-152-3p | CHUK | 0.2 | 0.90976 | -0.1 | 0.93218 | MirTarget | -0.1 | 0.04028 | NA | |
124 | hsa-miR-23b-3p | CHUK | -0.11 | 0.96135 | -0.1 | 0.93218 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.14 | 0.00997 | NA | |
125 | hsa-miR-339-5p | CHUK | -0.3 | 0.71291 | -0.1 | 0.93218 | miRanda | -0.06 | 0.00768 | NA | |
126 | hsa-miR-376c-3p | CHUK | 0.31 | 0.55869 | -0.1 | 0.93218 | MirTarget | -0.07 | 0.00486 | NA | |
127 | hsa-miR-497-5p | CHUK | -0.01 | 0.98915 | -0.1 | 0.93218 | MirTarget | -0.1 | 0.0051 | NA | |
128 | hsa-miR-15b-3p | CSF2RB | -0.56 | 0.60918 | -0.42 | 0.60801 | mirMAP | -0.56 | 0 | NA | |
129 | hsa-miR-186-5p | CSF2RB | -0.32 | 0.85413 | -0.42 | 0.60801 | mirMAP | -0.53 | 0.00037 | NA | |
130 | hsa-miR-19a-3p | CSF2RB | -0.21 | 0.84464 | -0.42 | 0.60801 | MirTarget | -0.51 | 0 | NA | |
131 | hsa-miR-19b-3p | CSF2RB | -0.03 | 0.98666 | -0.42 | 0.60801 | MirTarget | -0.67 | 0 | NA | |
132 | hsa-miR-30b-3p | CSF2RB | -0.51 | 0.16242 | -0.42 | 0.60801 | MirTarget | -0.43 | 2.0E-5 | NA | |
133 | hsa-miR-452-3p | CSF2RB | -0.17 | 0.79901 | -0.42 | 0.60801 | mirMAP | -0.43 | 0 | NA | |
134 | hsa-miR-532-5p | CSF2RB | -0.35 | 0.87895 | -0.42 | 0.60801 | MirTarget | -0.37 | 0.00041 | NA | |
135 | hsa-miR-576-5p | CSF2RB | -0.51 | 0.41719 | -0.42 | 0.60801 | miRNATAP | -0.36 | 0.0007 | NA | |
136 | hsa-miR-590-3p | CSF2RB | -0.28 | 0.59127 | -0.42 | 0.60801 | miRanda; mirMAP | -0.39 | 1.0E-5 | NA | |
137 | hsa-miR-625-5p | CSF2RB | -0.69 | 0.21031 | -0.42 | 0.60801 | MirTarget | -0.29 | 0.00017 | NA | |
138 | hsa-miR-139-5p | CYCS | -0.08 | 0.92869 | -0.08 | 0.96574 | miRanda | -0.18 | 7.0E-5 | NA | |
139 | hsa-miR-20b-5p | CYCS | 0.15 | 0.74358 | -0.08 | 0.96574 | mirMAP | -0.06 | 0.04037 | NA | |
140 | hsa-miR-34c-3p | CYCS | -0.07 | 0.82545 | -0.08 | 0.96574 | mirMAP | -0.1 | 0.008 | NA | |
141 | hsa-miR-34c-5p | CYCS | -0.02 | 0.95279 | -0.08 | 0.96574 | miRanda | -0.16 | 0.00033 | NA | |
142 | hsa-miR-127-3p | DFFA | 0.08 | 0.97263 | -0.29 | 0.79395 | miRanda | -0.09 | 0.02433 | NA | |
143 | hsa-miR-129-5p | DFFA | 0.27 | 0.55335 | -0.29 | 0.79395 | miRanda; mirMAP | -0.05 | 0.02088 | NA | |
144 | hsa-miR-145-5p | DFFA | 0.04 | 0.98758 | -0.29 | 0.79395 | miRNAWalker2 validate; miRTarBase | -0.09 | 0.00132 | NA | |
145 | hsa-miR-26a-5p | DFFA | 0.01 | 0.99772 | -0.29 | 0.79395 | mirMAP | -0.17 | 0.00684 | NA | |
146 | hsa-miR-30a-3p | DFFA | 0.25 | 0.91709 | -0.29 | 0.79395 | mirMAP | -0.15 | 0.00034 | NA | |
147 | hsa-miR-34c-5p | DFFA | -0.02 | 0.95279 | -0.29 | 0.79395 | miRanda | -0.11 | 0.00077 | NA | |
148 | hsa-miR-377-5p | DFFA | -0.18 | 0.59429 | -0.29 | 0.79395 | mirMAP | -0.06 | 0.01588 | NA | |
149 | hsa-miR-664a-3p | DFFA | -0 | 0.99612 | -0.29 | 0.79395 | mirMAP | -0.14 | 0.00043 | NA | |
150 | hsa-miR-199a-5p | DFFB | 0.16 | 0.9358 | -0.38 | 0.65788 | miRanda | -0.08 | 0.0348 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 46 | 1929 | 7.319e-33 | 3.406e-29 |
2 | INTRACELLULAR SIGNAL TRANSDUCTION | 43 | 1572 | 1.497e-32 | 3.482e-29 |
3 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 43 | 1848 | 1.258e-29 | 1.951e-26 |
4 | CELL DEATH | 34 | 1001 | 1.341e-27 | 1.248e-24 |
5 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 41 | 1791 | 1.333e-27 | 1.248e-24 |
6 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 37 | 1381 | 9.658e-27 | 6.42e-24 |
7 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 38 | 1492 | 8.338e-27 | 6.42e-24 |
8 | REGULATION OF CELL DEATH | 37 | 1472 | 9.284e-26 | 5.4e-23 |
9 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 17 | 99 | 1.733e-25 | 8.959e-23 |
10 | RESPONSE TO CYTOKINE | 29 | 714 | 2.606e-25 | 1.212e-22 |
11 | POSITIVE REGULATION OF CELL COMMUNICATION | 37 | 1532 | 3.807e-25 | 1.476e-22 |
12 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 38 | 1656 | 3.674e-25 | 1.476e-22 |
13 | APOPTOTIC SIGNALING PATHWAY | 22 | 289 | 6.858e-25 | 2.455e-22 |
14 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 36 | 1518 | 4.55e-24 | 1.512e-21 |
15 | IMMUNE SYSTEM PROCESS | 39 | 1984 | 1.724e-23 | 5.346e-21 |
16 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 29 | 876 | 8.211e-23 | 2.388e-20 |
17 | RESPONSE TO NITROGEN COMPOUND | 28 | 859 | 8.825e-22 | 2.415e-19 |
18 | REGULATION OF IMMUNE SYSTEM PROCESS | 33 | 1403 | 1.224e-21 | 3.164e-19 |
19 | NEGATIVE REGULATION OF CELL DEATH | 28 | 872 | 1.321e-21 | 3.236e-19 |
20 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 12 | 39 | 1.412e-21 | 3.286e-19 |
21 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 18 | 213 | 3.512e-21 | 7.783e-19 |
22 | POSITIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 17 | 179 | 6.7e-21 | 1.417e-18 |
23 | REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 18 | 233 | 1.804e-20 | 3.581e-18 |
24 | CELLULAR RESPONSE TO CYTOKINE STIMULUS | 24 | 606 | 1.847e-20 | 3.581e-18 |
25 | REGULATION OF KINASE ACTIVITY | 26 | 776 | 2.015e-20 | 3.751e-18 |
26 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 14 | 95 | 4.325e-20 | 7.741e-18 |
27 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 14 | 98 | 6.856e-20 | 1.182e-17 |
28 | REGULATION OF TRANSFERASE ACTIVITY | 27 | 946 | 1.84e-19 | 3.058e-17 |
29 | REGULATION OF IMMUNE RESPONSE | 26 | 858 | 2.447e-19 | 3.926e-17 |
30 | ZYMOGEN ACTIVATION | 14 | 112 | 4.886e-19 | 7.577e-17 |
31 | RESPONSE TO ENDOGENOUS STIMULUS | 31 | 1450 | 5.865e-19 | 8.804e-17 |
32 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 25 | 799 | 6.917e-19 | 1.006e-16 |
33 | PHOSPHORYLATION | 29 | 1228 | 9.02e-19 | 1.272e-16 |
34 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 15 | 153 | 1.032e-18 | 1.413e-16 |
35 | POSITIVE REGULATION OF KINASE ACTIVITY | 21 | 482 | 1.079e-18 | 1.434e-16 |
36 | POSITIVE REGULATION OF IMMUNE RESPONSE | 22 | 563 | 1.378e-18 | 1.781e-16 |
37 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 28 | 1135 | 1.454e-18 | 1.829e-16 |
38 | ACTIVATION OF IMMUNE RESPONSE | 20 | 427 | 2.061e-18 | 2.524e-16 |
39 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 19 | 363 | 2.15e-18 | 2.565e-16 |
40 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 34 | 1977 | 4.305e-18 | 5.008e-16 |
41 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 25 | 867 | 4.81e-18 | 5.459e-16 |
42 | CYTOKINE MEDIATED SIGNALING PATHWAY | 20 | 452 | 6.254e-18 | 6.856e-16 |
43 | POSITIVE REGULATION OF CELL DEATH | 22 | 605 | 6.336e-18 | 6.856e-16 |
44 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 17 | 279 | 1.349e-17 | 1.405e-15 |
45 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 31 | 1618 | 1.359e-17 | 1.405e-15 |
46 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 26 | 1036 | 2.501e-17 | 2.476e-15 |
47 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 26 | 1036 | 2.501e-17 | 2.476e-15 |
48 | PROTEIN PHOSPHORYLATION | 25 | 944 | 3.573e-17 | 3.463e-15 |
49 | POSITIVE REGULATION OF PEPTIDASE ACTIVITY | 14 | 154 | 4.851e-17 | 4.606e-15 |
50 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 20 | 505 | 5.366e-17 | 4.993e-15 |
51 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 21 | 616 | 1.549e-16 | 1.413e-14 |
52 | REGULATION OF PROTEOLYSIS | 22 | 711 | 1.881e-16 | 1.683e-14 |
53 | REGULATION OF PEPTIDASE ACTIVITY | 18 | 392 | 1.954e-16 | 1.716e-14 |
54 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 14 | 171 | 2.149e-16 | 1.851e-14 |
55 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 19 | 470 | 2.575e-16 | 2.179e-14 |
56 | REGULATION OF PROTEIN MODIFICATION PROCESS | 30 | 1710 | 6.517e-16 | 5.415e-14 |
57 | POSITIVE REGULATION OF DEFENSE RESPONSE | 17 | 364 | 1.152e-15 | 9.407e-14 |
58 | NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 14 | 200 | 1.951e-15 | 1.565e-13 |
59 | TOLL LIKE RECEPTOR SIGNALING PATHWAY | 11 | 85 | 2.589e-15 | 2.008e-13 |
60 | ACTIVATION OF INNATE IMMUNE RESPONSE | 14 | 204 | 2.574e-15 | 2.008e-13 |
61 | RESPONSE TO MOLECULE OF BACTERIAL ORIGIN | 16 | 321 | 3.254e-15 | 2.482e-13 |
62 | PROTEIN MATURATION | 15 | 265 | 4.092e-15 | 3.057e-13 |
63 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 13 | 4.139e-15 | 3.057e-13 |
64 | POSITIVE REGULATION OF PROTEOLYSIS | 16 | 363 | 2.21e-14 | 1.607e-12 |
65 | RESPONSE TO ABIOTIC STIMULUS | 23 | 1024 | 3.174e-14 | 2.272e-12 |
66 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 14 | 246 | 3.47e-14 | 2.447e-12 |
67 | PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 11 | 109 | 4.392e-14 | 3.05e-12 |
68 | POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 17 | 4.645e-14 | 3.178e-12 |
69 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 15 | 323 | 7.494e-14 | 5.054e-12 |
70 | REGULATION OF RESPONSE TO STRESS | 26 | 1468 | 1.023e-13 | 6.802e-12 |
71 | HOMEOSTATIC PROCESS | 25 | 1337 | 1.085e-13 | 7.111e-12 |
72 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 8 | 34 | 1.188e-13 | 7.677e-12 |
73 | NEURON APOPTOTIC PROCESS | 8 | 35 | 1.536e-13 | 9.791e-12 |
74 | RESPONSE TO BIOTIC STIMULUS | 21 | 886 | 2.004e-13 | 1.26e-11 |
75 | RESPONSE TO HORMONE | 21 | 893 | 2.333e-13 | 1.447e-11 |
76 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 13 | 228 | 3.064e-13 | 1.876e-11 |
77 | REGULATION OF INNATE IMMUNE RESPONSE | 15 | 357 | 3.207e-13 | 1.938e-11 |
78 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 15 | 360 | 3.62e-13 | 2.16e-11 |
79 | POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 11 | 132 | 3.745e-13 | 2.206e-11 |
80 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 22 | 4.022e-13 | 2.323e-11 |
81 | RESPONSE TO TUMOR NECROSIS FACTOR | 13 | 233 | 4.044e-13 | 2.323e-11 |
82 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 11 | 142 | 8.417e-13 | 4.776e-11 |
83 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 17 | 552 | 1.018e-12 | 5.706e-11 |
84 | I KAPPAB KINASE NF KAPPAB SIGNALING | 9 | 70 | 1.093e-12 | 6.055e-11 |
85 | WOUND HEALING | 16 | 470 | 1.165e-12 | 6.376e-11 |
86 | RESPONSE TO WOUNDING | 17 | 563 | 1.395e-12 | 7.549e-11 |
87 | REGULATION OF DEFENSE RESPONSE | 19 | 759 | 1.417e-12 | 7.579e-11 |
88 | CHEMICAL HOMEOSTASIS | 20 | 874 | 1.652e-12 | 8.662e-11 |
89 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 8 | 46 | 1.657e-12 | 8.662e-11 |
90 | RESPONSE TO PEPTIDE | 15 | 404 | 1.903e-12 | 9.839e-11 |
91 | NEURON DEATH | 8 | 47 | 1.992e-12 | 1.018e-10 |
92 | RESPONSE TO LIPID | 20 | 888 | 2.21e-12 | 1.118e-10 |
93 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 21 | 1008 | 2.385e-12 | 1.193e-10 |
94 | PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 8 | 49 | 2.842e-12 | 1.407e-10 |
95 | CELLULAR RESPONSE TO STRESS | 25 | 1565 | 3.636e-12 | 1.781e-10 |
96 | CELLULAR RESPONSE TO MECHANICAL STIMULUS | 9 | 80 | 3.802e-12 | 1.843e-10 |
97 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 16 | 514 | 4.505e-12 | 2.161e-10 |
98 | RESPONSE TO BACTERIUM | 16 | 528 | 6.748e-12 | 3.204e-10 |
99 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 8 | 55 | 7.56e-12 | 3.518e-10 |
100 | EXECUTION PHASE OF APOPTOSIS | 8 | 55 | 7.56e-12 | 3.518e-10 |
101 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 7 | 32 | 7.743e-12 | 3.532e-10 |
102 | NEGATIVE REGULATION OF SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 7 | 32 | 7.743e-12 | 3.532e-10 |
103 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 14 | 370 | 8.921e-12 | 4.03e-10 |
104 | SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 7 | 33 | 9.803e-12 | 4.344e-10 |
105 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 7 | 33 | 9.803e-12 | 4.344e-10 |
106 | INFLAMMATORY RESPONSE | 15 | 454 | 1.004e-11 | 4.405e-10 |
107 | ACTIVATION OF PROTEIN KINASE A ACTIVITY | 6 | 17 | 1.016e-11 | 4.42e-10 |
108 | REGULATION OF CELL PROLIFERATION | 24 | 1496 | 1.061e-11 | 4.572e-10 |
109 | RESPONSE TO EXTERNAL STIMULUS | 26 | 1821 | 1.441e-11 | 6.151e-10 |
110 | REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 10 | 144 | 2.968e-11 | 1.256e-09 |
111 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 19 | 905 | 3.01e-11 | 1.262e-09 |
112 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 12 | 263 | 3.726e-11 | 1.548e-09 |
113 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 19 | 917 | 3.774e-11 | 1.554e-09 |
114 | FC RECEPTOR SIGNALING PATHWAY | 11 | 206 | 4.888e-11 | 1.995e-09 |
115 | INTRINSIC APOPTOTIC SIGNALING PATHWAY | 10 | 152 | 5.084e-11 | 2.057e-09 |
116 | REGULATION OF HYDROLASE ACTIVITY | 22 | 1327 | 5.493e-11 | 2.203e-09 |
117 | CELLULAR RESPONSE TO PEPTIDE | 12 | 274 | 5.994e-11 | 2.384e-09 |
118 | CELLULAR GLUCOSE HOMEOSTASIS | 8 | 75 | 9.965e-11 | 3.929e-09 |
119 | IMMUNE RESPONSE | 20 | 1100 | 1.048e-10 | 4.099e-09 |
120 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 12 | 289 | 1.11e-10 | 4.303e-09 |
121 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 13 | 365 | 1.143e-10 | 4.394e-09 |
122 | TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 9 | 118 | 1.334e-10 | 5.088e-09 |
123 | PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 6 | 25 | 1.426e-10 | 5.394e-09 |
124 | GLUCOSE HOMEOSTASIS | 10 | 170 | 1.539e-10 | 5.728e-09 |
125 | CARBOHYDRATE HOMEOSTASIS | 10 | 170 | 1.539e-10 | 5.728e-09 |
126 | PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS | 9 | 120 | 1.552e-10 | 5.733e-09 |
127 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 9 | 121 | 1.673e-10 | 6.129e-09 |
128 | REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 7 | 50 | 2.197e-10 | 7.985e-09 |
129 | NIK NF KAPPAB SIGNALING | 8 | 83 | 2.284e-10 | 8.237e-09 |
130 | POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 7 | 51 | 2.54e-10 | 9.091e-09 |
131 | RESPONSE TO OXYGEN LEVELS | 12 | 311 | 2.58e-10 | 9.094e-09 |
132 | HEMOSTASIS | 12 | 311 | 2.58e-10 | 9.094e-09 |
133 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 9 | 129 | 2.975e-10 | 1.041e-08 |
134 | NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR SIGNALING PATHWAY | 6 | 28 | 3.011e-10 | 1.045e-08 |
135 | REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 6 | 29 | 3.786e-10 | 1.295e-08 |
136 | POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 6 | 29 | 3.786e-10 | 1.295e-08 |
137 | NEGATIVE REGULATION OF CELL COMMUNICATION | 20 | 1192 | 4.325e-10 | 1.469e-08 |
138 | POSITIVE REGULATION OF TRANSPORT | 18 | 936 | 4.631e-10 | 1.561e-08 |
139 | MYD88 INDEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 6 | 30 | 4.721e-10 | 1.58e-08 |
140 | PROTEOLYSIS | 20 | 1208 | 5.462e-10 | 1.815e-08 |
141 | ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 10 | 195 | 5.908e-10 | 1.922e-08 |
142 | REGULATION OF PROTEIN LOCALIZATION | 18 | 950 | 5.874e-10 | 1.922e-08 |
143 | LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 6 | 31 | 5.84e-10 | 1.922e-08 |
144 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 21 | 1360 | 6.338e-10 | 2.048e-08 |
145 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 8 | 95 | 6.83e-10 | 2.192e-08 |
146 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 11 | 264 | 6.899e-10 | 2.199e-08 |
147 | REGULATION OF INTRACELLULAR TRANSPORT | 15 | 621 | 7.932e-10 | 2.511e-08 |
148 | REGULATION OF CATABOLIC PROCESS | 16 | 731 | 8.189e-10 | 2.574e-08 |
149 | T CELL APOPTOTIC PROCESS | 5 | 15 | 8.382e-10 | 2.617e-08 |
150 | CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 6 | 33 | 8.741e-10 | 2.712e-08 |
151 | T CELL RECEPTOR SIGNALING PATHWAY | 9 | 146 | 8.989e-10 | 2.77e-08 |
152 | RENAL WATER HOMEOSTASIS | 6 | 34 | 1.059e-09 | 3.241e-08 |
153 | RESPONSE TO MECHANICAL STIMULUS | 10 | 210 | 1.215e-09 | 3.671e-08 |
154 | RENAL SYSTEM PROCESS | 8 | 102 | 1.211e-09 | 3.671e-08 |
155 | STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 8 | 103 | 1.31e-09 | 3.931e-08 |
156 | POSITIVE REGULATION OF PROTEIN IMPORT | 8 | 104 | 1.415e-09 | 4.221e-08 |
157 | POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 6 | 36 | 1.526e-09 | 4.522e-08 |
158 | CELLULAR RESPONSE TO HORMONE STIMULUS | 14 | 552 | 1.702e-09 | 5.012e-08 |
159 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 10 | 218 | 1.745e-09 | 5.108e-08 |
160 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 10 | 220 | 1.907e-09 | 5.545e-08 |
161 | CELLULAR RESPONSE TO GLUCAGON STIMULUS | 6 | 38 | 2.152e-09 | 6.219e-08 |
162 | LYMPHOCYTE APOPTOTIC PROCESS | 5 | 18 | 2.374e-09 | 6.818e-08 |
163 | REGULATION OF MEMBRANE PERMEABILITY | 7 | 70 | 2.508e-09 | 7.159e-08 |
164 | RESPONSE TO AMINO ACID | 8 | 112 | 2.561e-09 | 7.222e-08 |
165 | REGULATION OF ORGANELLE ORGANIZATION | 19 | 1178 | 2.559e-09 | 7.222e-08 |
166 | RESPONSE TO CARBOHYDRATE | 9 | 168 | 3.113e-09 | 8.725e-08 |
167 | CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS | 7 | 74 | 3.727e-09 | 1.039e-07 |
168 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 18 | 1079 | 4.419e-09 | 1.224e-07 |
169 | REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 6 | 43 | 4.693e-09 | 1.285e-07 |
170 | CELLULAR COMPONENT DISASSEMBLY INVOLVED IN EXECUTION PHASE OF APOPTOSIS | 6 | 43 | 4.693e-09 | 1.285e-07 |
171 | REGULATION OF MAP KINASE ACTIVITY | 11 | 319 | 5.015e-09 | 1.357e-07 |
172 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 12 | 404 | 4.996e-09 | 1.357e-07 |
173 | NECROPTOTIC PROCESS | 5 | 21 | 5.596e-09 | 1.505e-07 |
174 | INOSITOL LIPID MEDIATED SIGNALING | 8 | 124 | 5.754e-09 | 1.539e-07 |
175 | REGULATION OF PROTEIN IMPORT | 9 | 183 | 6.593e-09 | 1.753e-07 |
176 | REGULATION OF NEURON DEATH | 10 | 252 | 7.035e-09 | 1.86e-07 |
177 | LEUKOCYTE APOPTOTIC PROCESS | 5 | 23 | 9.209e-09 | 2.421e-07 |
178 | RESPONSE TO GLUCAGON | 6 | 48 | 9.33e-09 | 2.439e-07 |
179 | PHOSPHATIDYLINOSITOL METABOLIC PROCESS | 9 | 193 | 1.049e-08 | 2.727e-07 |
180 | RESPONSE TO OXIDATIVE STRESS | 11 | 352 | 1.388e-08 | 3.589e-07 |
181 | MULTICELLULAR ORGANISMAL HOMEOSTASIS | 10 | 272 | 1.457e-08 | 3.744e-07 |
182 | NEGATIVE REGULATION OF CATABOLIC PROCESS | 9 | 203 | 1.628e-08 | 4.161e-07 |
183 | REGULATION OF MAPK CASCADE | 14 | 660 | 1.649e-08 | 4.194e-07 |
184 | MITOCHONDRIAL MEMBRANE ORGANIZATION | 7 | 92 | 1.735e-08 | 4.387e-07 |
185 | REGULATION OF TRANSPORT | 22 | 1804 | 1.767e-08 | 4.444e-07 |
186 | REGULATION OF NECROTIC CELL DEATH | 5 | 26 | 1.787e-08 | 4.47e-07 |
187 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 9 | 207 | 1.928e-08 | 4.797e-07 |
188 | GLYCEROLIPID BIOSYNTHETIC PROCESS | 9 | 211 | 2.275e-08 | 5.631e-07 |
189 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 12 | 465 | 2.379e-08 | 5.826e-07 |
190 | CELL ACTIVATION | 13 | 568 | 2.377e-08 | 5.826e-07 |
191 | NECROTIC CELL DEATH | 5 | 28 | 2.657e-08 | 6.472e-07 |
192 | POSITIVE REGULATION OF MAPK CASCADE | 12 | 470 | 2.676e-08 | 6.485e-07 |
193 | LIPID PHOSPHORYLATION | 7 | 99 | 2.897e-08 | 6.984e-07 |
194 | REGULATION OF MITOCHONDRION ORGANIZATION | 9 | 218 | 3.016e-08 | 7.197e-07 |
195 | MULTICELLULAR ORGANISMAL WATER HOMEOSTASIS | 6 | 58 | 3.002e-08 | 7.197e-07 |
196 | REGULATION OF NECROPTOTIC PROCESS | 4 | 11 | 3.094e-08 | 7.307e-07 |
197 | POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 4 | 11 | 3.094e-08 | 7.307e-07 |
198 | RESPONSE TO INORGANIC SUBSTANCE | 12 | 479 | 3.296e-08 | 7.746e-07 |
199 | DEFENSE RESPONSE | 18 | 1231 | 3.406e-08 | 7.963e-07 |
200 | POSITIVE REGULATION OF GENE EXPRESSION | 21 | 1733 | 4.685e-08 | 1.09e-06 |
201 | CELLULAR RESPONSE TO BIOTIC STIMULUS | 8 | 163 | 4.922e-08 | 1.139e-06 |
202 | PHOSPHOLIPID BIOSYNTHETIC PROCESS | 9 | 235 | 5.753e-08 | 1.325e-06 |
203 | REGULATION OF CELLULAR LOCALIZATION | 18 | 1277 | 5.958e-08 | 1.366e-06 |
204 | REGULATION OF BODY FLUID LEVELS | 12 | 506 | 6.003e-08 | 1.369e-06 |
205 | RESPONSE TO ACID CHEMICAL | 10 | 319 | 6.544e-08 | 1.485e-06 |
206 | HEPATOCYTE APOPTOTIC PROCESS | 4 | 13 | 6.671e-08 | 1.499e-06 |
207 | INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY | 4 | 13 | 6.671e-08 | 1.499e-06 |
208 | T CELL HOMEOSTASIS | 5 | 34 | 7.412e-08 | 1.658e-06 |
209 | REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY | 4 | 14 | 9.316e-08 | 2.074e-06 |
210 | WATER HOMEOSTASIS | 6 | 70 | 9.438e-08 | 2.091e-06 |
211 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 6 | 71 | 1.028e-07 | 2.268e-06 |
212 | LEUKOCYTE CELL CELL ADHESION | 9 | 255 | 1.156e-07 | 2.537e-06 |
213 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 9 | 258 | 1.277e-07 | 2.789e-06 |
214 | LEUKOCYTE MIGRATION | 9 | 259 | 1.319e-07 | 2.868e-06 |
215 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 7 | 126 | 1.536e-07 | 3.324e-06 |
216 | RESPONSE TO REACTIVE OXYGEN SPECIES | 8 | 191 | 1.674e-07 | 3.606e-06 |
217 | CELLULAR HOMEOSTASIS | 13 | 676 | 1.799e-07 | 3.857e-06 |
218 | CELLULAR CHEMICAL HOMEOSTASIS | 12 | 570 | 2.176e-07 | 4.644e-06 |
219 | REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 4 | 17 | 2.199e-07 | 4.673e-06 |
220 | JNK CASCADE | 6 | 82 | 2.446e-07 | 5.174e-06 |
221 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 9 | 282 | 2.71e-07 | 5.653e-06 |
222 | REGULATION OF LIPID METABOLIC PROCESS | 9 | 282 | 2.71e-07 | 5.653e-06 |
223 | RESPONSE TO ALKALOID | 7 | 137 | 2.722e-07 | 5.653e-06 |
224 | ACTIVATION OF MAPK ACTIVITY | 7 | 137 | 2.722e-07 | 5.653e-06 |
225 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 14 | 829 | 2.753e-07 | 5.692e-06 |
226 | REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 5 | 44 | 2.822e-07 | 5.811e-06 |
227 | REGULATION OF CYTOPLASMIC TRANSPORT | 11 | 481 | 3.272e-07 | 6.706e-06 |
228 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 10 | 381 | 3.393e-07 | 6.894e-06 |
229 | MITOCHONDRION ORGANIZATION | 12 | 594 | 3.382e-07 | 6.894e-06 |
230 | REGULATION OF CELL ACTIVATION | 11 | 484 | 3.48e-07 | 7.04e-06 |
231 | LEUKOCYTE DIFFERENTIATION | 9 | 292 | 3.634e-07 | 7.319e-06 |
232 | CELLULAR RESPONSE TO INTERLEUKIN 1 | 6 | 88 | 3.73e-07 | 7.481e-06 |
233 | GLYCEROPHOSPHOLIPID METABOLIC PROCESS | 9 | 297 | 4.19e-07 | 8.367e-06 |
234 | RESPONSE TO TEMPERATURE STIMULUS | 7 | 148 | 4.6e-07 | 9.115e-06 |
235 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 15 | 1004 | 4.603e-07 | 9.115e-06 |
236 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 20 | 1805 | 4.655e-07 | 9.177e-06 |
237 | LYMPHOCYTE HOMEOSTASIS | 5 | 50 | 5.426e-07 | 1.065e-05 |
238 | NEGATIVE REGULATION OF LIPID CATABOLIC PROCESS | 4 | 21 | 5.477e-07 | 1.071e-05 |
239 | REGULATION OF PROTEIN TARGETING | 9 | 307 | 5.528e-07 | 1.076e-05 |
240 | RESPONSE TO NICOTINE | 5 | 51 | 6.001e-07 | 1.163e-05 |
241 | REGULATION OF CELL ADHESION | 12 | 629 | 6.209e-07 | 1.199e-05 |
242 | RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 4 | 22 | 6.679e-07 | 1.284e-05 |
243 | REGULATION OF GLUCOSE TRANSPORT | 6 | 100 | 7.963e-07 | 1.525e-05 |
244 | REGULATION OF EXECUTION PHASE OF APOPTOSIS | 4 | 24 | 9.655e-07 | 1.841e-05 |
245 | POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION | 7 | 167 | 1.039e-06 | 1.973e-05 |
246 | APOPTOTIC MITOCHONDRIAL CHANGES | 5 | 57 | 1.054e-06 | 1.993e-05 |
247 | RESPONSE TO METAL ION | 9 | 333 | 1.087e-06 | 2.048e-05 |
248 | INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 6 | 106 | 1.123e-06 | 2.106e-05 |
249 | EPITHELIAL CELL APOPTOTIC PROCESS | 4 | 25 | 1.147e-06 | 2.143e-05 |
250 | REGULATION OF AUTOPHAGY | 8 | 249 | 1.251e-06 | 2.322e-05 |
251 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 15 | 1087 | 1.253e-06 | 2.322e-05 |
252 | NEGATIVE REGULATION OF KINASE ACTIVITY | 8 | 250 | 1.289e-06 | 2.381e-05 |
253 | REGULATION OF GLUCOSE IMPORT | 5 | 60 | 1.365e-06 | 2.49e-05 |
254 | LYMPHOCYTE ACTIVATION | 9 | 342 | 1.355e-06 | 2.49e-05 |
255 | LEUKOCYTE HOMEOSTASIS | 5 | 60 | 1.365e-06 | 2.49e-05 |
256 | RESPONSE TO CORTICOSTEROID | 7 | 176 | 1.476e-06 | 2.684e-05 |
257 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 12 | 684 | 1.496e-06 | 2.709e-05 |
258 | MITOCHONDRIAL TRANSPORT | 7 | 177 | 1.533e-06 | 2.766e-05 |
259 | DNA CATABOLIC PROCESS | 4 | 27 | 1.583e-06 | 2.844e-05 |
260 | CELLULAR RESPONSE TO LIPID | 10 | 457 | 1.767e-06 | 3.162e-05 |
261 | RESPONSE TO INTERLEUKIN 1 | 6 | 115 | 1.811e-06 | 3.228e-05 |
262 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 11 | 573 | 1.821e-06 | 3.234e-05 |
263 | SINGLE ORGANISM CELL ADHESION | 10 | 459 | 1.837e-06 | 3.251e-05 |
264 | GLYCEROLIPID METABOLIC PROCESS | 9 | 356 | 1.885e-06 | 3.323e-05 |
265 | POSITIVE REGULATION OF NIK NF KAPPAB SIGNALING | 4 | 29 | 2.132e-06 | 3.744e-05 |
266 | RESPONSE TO ALCOHOL | 9 | 362 | 2.163e-06 | 3.783e-05 |
267 | PHOSPHOLIPID METABOLIC PROCESS | 9 | 364 | 2.263e-06 | 3.943e-05 |
268 | POSITIVE REGULATION OF NEURON DEATH | 5 | 67 | 2.372e-06 | 4.118e-05 |
269 | REGULATION OF NEURON APOPTOTIC PROCESS | 7 | 192 | 2.635e-06 | 4.558e-05 |
270 | NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS | 9 | 372 | 2.703e-06 | 4.658e-05 |
271 | MYD88 DEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 4 | 32 | 3.205e-06 | 5.48e-05 |
272 | REGULATION OF CELL CELL ADHESION | 9 | 380 | 3.215e-06 | 5.48e-05 |
273 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 4 | 32 | 3.205e-06 | 5.48e-05 |
274 | REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION | 6 | 128 | 3.379e-06 | 5.739e-05 |
275 | PROTEIN KINASE B SIGNALING | 4 | 34 | 4.114e-06 | 6.936e-05 |
276 | CELLULAR RESPONSE TO ALKALOID | 4 | 34 | 4.114e-06 | 6.936e-05 |
277 | REGULATION OF INFLAMMATORY RESPONSE | 8 | 294 | 4.298e-06 | 7.22e-05 |
278 | LIPID MODIFICATION | 7 | 210 | 4.763e-06 | 7.972e-05 |
279 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 6 | 138 | 5.222e-06 | 8.709e-05 |
280 | NEGATIVE REGULATION OF LIPID METABOLIC PROCESS | 5 | 80 | 5.719e-06 | 9.469e-05 |
281 | INSULIN RECEPTOR SIGNALING PATHWAY | 5 | 80 | 5.719e-06 | 9.469e-05 |
282 | REGULATION OF HOMOTYPIC CELL CELL ADHESION | 8 | 307 | 5.905e-06 | 9.744e-05 |
283 | RESPONSE TO ESTROGEN | 7 | 218 | 6.088e-06 | 0.0001001 |
284 | PLATELET ACTIVATION | 6 | 142 | 6.157e-06 | 0.0001009 |
285 | CELLULAR RESPONSE TO OXYGEN LEVELS | 6 | 143 | 6.411e-06 | 0.0001047 |
286 | LEUKOCYTE ACTIVATION | 9 | 414 | 6.438e-06 | 0.0001047 |
287 | REGULATION OF PROTEIN MATURATION | 5 | 82 | 6.459e-06 | 0.0001047 |
288 | REGULATION OF VITAMIN METABOLIC PROCESS | 3 | 12 | 6.735e-06 | 0.0001084 |
289 | POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 3 | 12 | 6.735e-06 | 0.0001084 |
290 | REGULATION OF HEMOPOIESIS | 8 | 314 | 6.964e-06 | 0.0001117 |
291 | RESPONSE TO ESTRADIOL | 6 | 146 | 7.223e-06 | 0.0001155 |
292 | PEPTIDYL SERINE MODIFICATION | 6 | 148 | 7.81e-06 | 0.000124 |
293 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 18 | 1784 | 7.8e-06 | 0.000124 |
294 | REGULATION OF CELL CYCLE | 13 | 949 | 7.869e-06 | 0.0001245 |
295 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 4 | 40 | 7.991e-06 | 0.000126 |
296 | RESPONSE TO COBALT ION | 3 | 13 | 8.736e-06 | 0.0001373 |
297 | RESPONSE TO DRUG | 9 | 431 | 8.894e-06 | 0.0001393 |
298 | REGULATION OF LEUKOCYTE DIFFERENTIATION | 7 | 232 | 9.143e-06 | 0.0001418 |
299 | REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 6 | 152 | 9.099e-06 | 0.0001418 |
300 | NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 5 | 88 | 9.138e-06 | 0.0001418 |
301 | RESPONSE TO HEAT | 5 | 89 | 9.658e-06 | 0.0001493 |
302 | REGULATION OF NIK NF KAPPAB SIGNALING | 4 | 42 | 9.74e-06 | 0.0001496 |
303 | POSITIVE REGULATION OF GLUCOSE TRANSPORT | 4 | 42 | 9.74e-06 | 0.0001496 |
304 | NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 9 | 437 | 9.934e-06 | 0.0001521 |
305 | NEGATIVE REGULATION OF CELLULAR CATABOLIC PROCESS | 6 | 156 | 1.056e-05 | 0.000161 |
306 | TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY | 3 | 14 | 1.109e-05 | 0.0001687 |
307 | REGULATION OF CYTOKINE PRODUCTION | 10 | 563 | 1.114e-05 | 0.0001688 |
308 | RESPONSE TO TOXIC SUBSTANCE | 7 | 241 | 1.171e-05 | 0.0001769 |
309 | POSITIVE REGULATION OF CELL CELL ADHESION | 7 | 243 | 1.235e-05 | 0.000186 |
310 | ORGANOPHOSPHATE BIOSYNTHETIC PROCESS | 9 | 450 | 1.255e-05 | 0.0001884 |
311 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 14 | 1152 | 1.302e-05 | 0.0001948 |
312 | RESPONSE TO VIRUS | 7 | 247 | 1.373e-05 | 0.0002048 |
313 | APOPTOTIC DNA FRAGMENTATION | 3 | 15 | 1.383e-05 | 0.0002057 |
314 | IMMUNE SYSTEM DEVELOPMENT | 10 | 582 | 1.484e-05 | 0.00022 |
315 | POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS | 4 | 47 | 1.534e-05 | 0.0002265 |
316 | NEGATIVE REGULATION OF TRANSFERASE ACTIVITY | 8 | 351 | 1.563e-05 | 0.0002294 |
317 | CELLULAR PROCESS INVOLVED IN REPRODUCTION IN MULTICELLULAR ORGANISM | 7 | 252 | 1.563e-05 | 0.0002294 |
318 | CELLULAR RESPONSE TO DNA DAMAGE STIMULUS | 11 | 720 | 1.592e-05 | 0.0002329 |
319 | INTRACELLULAR RECEPTOR SIGNALING PATHWAY | 6 | 168 | 1.61e-05 | 0.0002348 |
320 | REGULATION OF LIPID KINASE ACTIVITY | 4 | 48 | 1.669e-05 | 0.0002427 |
321 | GAMETE GENERATION | 10 | 595 | 1.795e-05 | 0.0002603 |
322 | STRIATED MUSCLE CELL DIFFERENTIATION | 6 | 173 | 1.9e-05 | 0.0002746 |
323 | RESPONSE TO GAMMA RADIATION | 4 | 50 | 1.966e-05 | 0.0002832 |
324 | DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 10 | 602 | 1.985e-05 | 0.0002851 |
325 | CELLULAR RESPONSE TO ACID CHEMICAL | 6 | 175 | 2.028e-05 | 0.0002904 |
326 | ACTIVATION OF NF KAPPAB INDUCING KINASE ACTIVITY | 3 | 17 | 2.058e-05 | 0.000292 |
327 | REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 3 | 17 | 2.058e-05 | 0.000292 |
328 | NEGATIVE REGULATION OF ANOIKIS | 3 | 17 | 2.058e-05 | 0.000292 |
329 | AGING | 7 | 264 | 2.109e-05 | 0.0002982 |
330 | CELL CELL ADHESION | 10 | 608 | 2.161e-05 | 0.0003047 |
331 | EMBRYO DEVELOPMENT | 12 | 894 | 2.269e-05 | 0.000319 |
332 | POSITIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY | 4 | 52 | 2.3e-05 | 0.0003214 |
333 | REGULATION OF LIPID CATABOLIC PROCESS | 4 | 52 | 2.3e-05 | 0.0003214 |
334 | IMMUNE EFFECTOR PROCESS | 9 | 486 | 2.307e-05 | 0.0003214 |
335 | INOSITOL PHOSPHATE MEDIATED SIGNALING | 3 | 18 | 2.464e-05 | 0.0003423 |
336 | CELLULAR RESPONSE TO AMINO ACID STIMULUS | 4 | 53 | 2.482e-05 | 0.0003427 |
337 | POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 4 | 53 | 2.482e-05 | 0.0003427 |
338 | RESPONSE TO KETONE | 6 | 182 | 2.53e-05 | 0.0003484 |
339 | RESPONSE TO HYDROGEN PEROXIDE | 5 | 109 | 2.588e-05 | 0.0003552 |
340 | REGULATION OF MYELOID CELL DIFFERENTIATION | 6 | 183 | 2.61e-05 | 0.0003572 |
341 | RESPONSE TO STEROID HORMONE | 9 | 497 | 2.75e-05 | 0.0003752 |
342 | MULTICELLULAR ORGANISM REPRODUCTION | 11 | 768 | 2.888e-05 | 0.0003929 |
343 | NEGATIVE REGULATION OF MEIOTIC CELL CYCLE | 3 | 19 | 2.92e-05 | 0.0003949 |
344 | DNA CATABOLIC PROCESS ENDONUCLEOLYTIC | 3 | 19 | 2.92e-05 | 0.0003949 |
345 | PROTEIN DEPHOSPHORYLATION | 6 | 190 | 3.223e-05 | 0.0004346 |
346 | PROTEIN AUTOPHOSPHORYLATION | 6 | 192 | 3.417e-05 | 0.0004596 |
347 | REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 4 | 59 | 3.803e-05 | 0.0005099 |
348 | REGULATION OF MONOOXYGENASE ACTIVITY | 4 | 60 | 4.064e-05 | 0.0005434 |
349 | REGULATION OF B CELL ACTIVATION | 5 | 121 | 4.276e-05 | 0.0005701 |
350 | REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 4 | 61 | 4.339e-05 | 0.0005769 |
351 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 12 | 957 | 4.419e-05 | 0.0005858 |
352 | REPRODUCTION | 14 | 1297 | 4.85e-05 | 0.0006411 |
353 | POSITIVE REGULATION OF CELL PROLIFERATION | 11 | 814 | 4.905e-05 | 0.0006465 |
354 | REGULATION OF RESPONSE TO WOUNDING | 8 | 413 | 4.976e-05 | 0.0006522 |
355 | RESPONSE TO RADIATION | 8 | 413 | 4.976e-05 | 0.0006522 |
356 | PROTEIN COMPLEX BIOGENESIS | 13 | 1132 | 5.04e-05 | 0.0006561 |
357 | CELL PROLIFERATION | 10 | 672 | 5.048e-05 | 0.0006561 |
358 | PROTEIN COMPLEX ASSEMBLY | 13 | 1132 | 5.04e-05 | 0.0006561 |
359 | LIPID BIOSYNTHETIC PROCESS | 9 | 539 | 5.167e-05 | 0.0006697 |
360 | POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 3 | 23 | 5.287e-05 | 0.0006834 |
361 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 9 | 541 | 5.317e-05 | 0.0006834 |
362 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 9 | 541 | 5.317e-05 | 0.0006834 |
363 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 16 | 1672 | 5.43e-05 | 0.0006961 |
364 | LYMPHOCYTE DIFFERENTIATION | 6 | 209 | 5.486e-05 | 0.0007012 |
365 | ESTABLISHMENT OF LOCALIZATION IN CELL | 16 | 1676 | 5.589e-05 | 0.0007122 |
366 | REGULATION OF CELL DIFFERENTIATION | 15 | 1492 | 5.602e-05 | 0.0007122 |
367 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 12 | 983 | 5.727e-05 | 0.0007261 |
368 | NEGATIVE REGULATION OF PHOSPHORYLATION | 8 | 422 | 5.789e-05 | 0.000732 |
369 | NUCLEAR IMPORT | 5 | 129 | 5.805e-05 | 0.000732 |
370 | POSITIVE REGULATION OF CELL ACTIVATION | 7 | 311 | 5.976e-05 | 0.0007515 |
371 | REGULATION OF ANOIKIS | 3 | 24 | 6.029e-05 | 0.0007561 |
372 | POSITIVE REGULATION OF LEUKOCYTE DIFFERENTIATION | 5 | 131 | 6.246e-05 | 0.0007813 |
373 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 9 | 554 | 6.383e-05 | 0.0007962 |
374 | B CELL ACTIVATION | 5 | 132 | 6.476e-05 | 0.0008057 |
375 | NEGATIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 4 | 68 | 6.659e-05 | 0.0008262 |
376 | CELLULAR EXTRAVASATION | 3 | 25 | 6.835e-05 | 0.0008436 |
377 | APOPTOTIC NUCLEAR CHANGES | 3 | 25 | 6.835e-05 | 0.0008436 |
378 | PROTEIN OLIGOMERIZATION | 8 | 434 | 7.044e-05 | 0.000867 |
379 | DEVELOPMENTAL PROGRAMMED CELL DEATH | 3 | 26 | 7.709e-05 | 0.0009465 |
380 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 4 | 74 | 9.274e-05 | 0.001136 |
381 | POSITIVE REGULATION OF ACUTE INFLAMMATORY RESPONSE | 3 | 28 | 9.669e-05 | 0.001175 |
382 | POSITIVE REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 3 | 28 | 9.669e-05 | 0.001175 |
383 | MODULATION BY SYMBIONT OF HOST CELLULAR PROCESS | 3 | 28 | 9.669e-05 | 0.001175 |
384 | GRANULOCYTE MIGRATION | 4 | 75 | 9.773e-05 | 0.001184 |
385 | RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 6 | 233 | 9.997e-05 | 0.001208 |
386 | SEXUAL REPRODUCTION | 10 | 730 | 0.0001005 | 0.001211 |
387 | RESPONSE TO IONIZING RADIATION | 5 | 145 | 0.000101 | 0.001212 |
388 | REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY | 5 | 145 | 0.000101 | 0.001212 |
389 | ORGANOPHOSPHATE METABOLIC PROCESS | 11 | 885 | 0.0001037 | 0.001241 |
390 | CELLULAR RESPONSE TO INSULIN STIMULUS | 5 | 146 | 0.0001044 | 0.001245 |
391 | PROTEIN IMPORT INTO NUCLEUS TRANSLOCATION | 3 | 29 | 0.0001076 | 0.001274 |
392 | MUSCLE ADAPTATION | 3 | 29 | 0.0001076 | 0.001274 |
393 | POSITIVE REGULATION OF MONOOXYGENASE ACTIVITY | 3 | 29 | 0.0001076 | 0.001274 |
394 | MUSCLE CELL DIFFERENTIATION | 6 | 237 | 0.0001097 | 0.001296 |
395 | LYMPHOCYTE COSTIMULATION | 4 | 78 | 0.0001139 | 0.001341 |
396 | SYSTEM PROCESS | 16 | 1785 | 0.0001182 | 0.001389 |
397 | NEGATIVE REGULATION OF B CELL ACTIVATION | 3 | 30 | 0.0001193 | 0.001398 |
398 | RESPONSE TO GROWTH FACTOR | 8 | 475 | 0.0001316 | 0.001539 |
399 | CELL DEVELOPMENT | 14 | 1426 | 0.0001342 | 0.001565 |
400 | CELLULAR LIPID METABOLIC PROCESS | 11 | 913 | 0.0001365 | 0.001588 |
401 | PROTEIN IMPORT | 5 | 155 | 0.0001382 | 0.001604 |
402 | PROTEIN LOCALIZATION TO NUCLEUS | 5 | 156 | 0.0001425 | 0.001649 |
403 | NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 9 | 616 | 0.0001429 | 0.00165 |
404 | ESTABLISHMENT OF PROTEIN LOCALIZATION TO ORGANELLE | 7 | 361 | 0.0001512 | 0.001741 |
405 | REGULATION OF JNK CASCADE | 5 | 159 | 0.0001557 | 0.001789 |
406 | POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 4 | 86 | 0.0001663 | 0.001906 |
407 | REGULATION OF PEPTIDE TRANSPORT | 6 | 256 | 0.0001671 | 0.00191 |
408 | POSITIVE REGULATION OF HEMOPOIESIS | 5 | 163 | 0.0001749 | 0.001995 |
409 | POSITIVE REGULATION OF CYTOKINE PRODUCTION | 7 | 370 | 0.0001759 | 0.002001 |
410 | POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 4 | 88 | 0.0001818 | 0.002063 |
411 | NEGATIVE REGULATION OF PROTEIN PROCESSING | 3 | 35 | 0.0001901 | 0.002147 |
412 | NEGATIVE REGULATION OF PROTEIN MATURATION | 3 | 35 | 0.0001901 | 0.002147 |
413 | POSITIVE REGULATION OF CELL ADHESION | 7 | 376 | 0.0001941 | 0.002187 |
414 | REGULATION OF OXIDOREDUCTASE ACTIVITY | 4 | 90 | 0.0001982 | 0.002222 |
415 | CALCIUM MEDIATED SIGNALING | 4 | 90 | 0.0001982 | 0.002222 |
416 | NEGATIVE REGULATION OF PROTEIN COMPLEX DISASSEMBLY | 5 | 170 | 0.0002127 | 0.002379 |
417 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 10 | 801 | 0.0002141 | 0.002389 |
418 | NEGATIVE REGULATION OF NEURON DEATH | 5 | 171 | 0.0002186 | 0.002433 |
419 | MODULATION BY VIRUS OF HOST MORPHOLOGY OR PHYSIOLOGY | 3 | 37 | 0.0002247 | 0.002495 |
420 | CELLULAR COMPONENT DISASSEMBLY | 8 | 515 | 0.0002284 | 0.00253 |
421 | NEGATIVE REGULATION OF ORGANELLE ORGANIZATION | 7 | 387 | 0.0002314 | 0.002558 |
422 | REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS | 4 | 94 | 0.0002343 | 0.002584 |
423 | FC GAMMA RECEPTOR SIGNALING PATHWAY | 4 | 95 | 0.000244 | 0.002672 |
424 | HOMEOSTASIS OF NUMBER OF CELLS | 5 | 175 | 0.0002433 | 0.002672 |
425 | REGULATION OF LIPID TRANSPORT | 4 | 95 | 0.000244 | 0.002672 |
426 | MYELOID LEUKOCYTE DIFFERENTIATION | 4 | 96 | 0.000254 | 0.002768 |
427 | FEMALE GAMETE GENERATION | 4 | 96 | 0.000254 | 0.002768 |
428 | WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY | 3 | 39 | 0.0002631 | 0.002853 |
429 | ERBB2 SIGNALING PATHWAY | 3 | 39 | 0.0002631 | 0.002853 |
430 | PROTEIN COMPLEX SUBUNIT ORGANIZATION | 14 | 1527 | 0.0002742 | 0.002967 |
431 | REGULATION OF MEIOTIC CELL CYCLE | 3 | 40 | 0.0002837 | 0.003063 |
432 | MYELOID LEUKOCYTE MIGRATION | 4 | 99 | 0.0002858 | 0.003078 |
433 | REGULATION OF LIPID STORAGE | 3 | 41 | 0.0003054 | 0.00326 |
434 | MITOTIC SPINDLE ASSEMBLY | 3 | 41 | 0.0003054 | 0.00326 |
435 | MICROTUBULE CYTOSKELETON ORGANIZATION INVOLVED IN MITOSIS | 3 | 41 | 0.0003054 | 0.00326 |
436 | DEPHOSPHORYLATION | 6 | 286 | 0.0003034 | 0.00326 |
437 | REGULATION OF CELLULAR RESPONSE TO STRESS | 9 | 691 | 0.0003353 | 0.00357 |
438 | MYELOID CELL DIFFERENTIATION | 5 | 189 | 0.0003469 | 0.003686 |
439 | MYELOID LEUKOCYTE MEDIATED IMMUNITY | 3 | 43 | 0.000352 | 0.003731 |
440 | REGULATION OF CELL CYCLE PROCESS | 8 | 558 | 0.0003912 | 0.004137 |
441 | REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 4 | 108 | 0.0003982 | 0.004202 |
442 | POSITIVE REGULATION OF INTERLEUKIN 8 PRODUCTION | 3 | 45 | 0.0004029 | 0.004218 |
443 | MODIFICATION BY SYMBIONT OF HOST MORPHOLOGY OR PHYSIOLOGY | 3 | 45 | 0.0004029 | 0.004218 |
444 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 13 | 1395 | 0.0004034 | 0.004218 |
445 | REGULATION OF ALCOHOL BIOSYNTHETIC PROCESS | 3 | 45 | 0.0004029 | 0.004218 |
446 | MACROMOLECULAR COMPLEX ASSEMBLY | 13 | 1398 | 0.0004118 | 0.004296 |
447 | REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 5 | 197 | 0.0004195 | 0.004366 |
448 | PEPTIDYL THREONINE MODIFICATION | 3 | 46 | 0.00043 | 0.004466 |
449 | NEGATIVE REGULATION OF CELL CYCLE | 7 | 433 | 0.0004555 | 0.004721 |
450 | POSITIVE REGULATION OF OXIDOREDUCTASE ACTIVITY | 3 | 47 | 0.0004583 | 0.004728 |
451 | RESPONSE TO ANTIBIOTIC | 3 | 47 | 0.0004583 | 0.004728 |
452 | PROTEIN HETEROOLIGOMERIZATION | 4 | 113 | 0.0004728 | 0.004867 |
453 | POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS | 3 | 48 | 0.0004877 | 0.004988 |
454 | REGULATION OF NF KAPPAB IMPORT INTO NUCLEUS | 3 | 48 | 0.0004877 | 0.004988 |
455 | REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO PLASMA MEMBRANE | 3 | 48 | 0.0004877 | 0.004988 |
456 | MULTI ORGANISM REPRODUCTIVE PROCESS | 10 | 891 | 0.0004985 | 0.005087 |
457 | RESPONSE TO INSULIN | 5 | 205 | 0.0005029 | 0.005121 |
458 | REGULATION OF LEUKOCYTE PROLIFERATION | 5 | 206 | 0.0005142 | 0.005224 |
459 | REGULATION OF TOLL LIKE RECEPTOR SIGNALING PATHWAY | 3 | 49 | 0.0005184 | 0.005243 |
460 | REGULATION OF STEROID BIOSYNTHETIC PROCESS | 3 | 49 | 0.0005184 | 0.005243 |
461 | SINGLE ORGANISM CELLULAR LOCALIZATION | 10 | 898 | 0.0005299 | 0.005349 |
462 | REGULATION OF FEVER GENERATION | 2 | 11 | 0.0005442 | 0.005469 |
463 | NEGATIVE REGULATION OF NECROTIC CELL DEATH | 2 | 11 | 0.0005442 | 0.005469 |
464 | REGULATION OF HOMEOSTATIC PROCESS | 7 | 447 | 0.0005505 | 0.005473 |
465 | NEGATIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 5 | 209 | 0.0005491 | 0.005473 |
466 | REGULATION OF PEPTIDE SECRETION | 5 | 209 | 0.0005491 | 0.005473 |
467 | GERM CELL DEVELOPMENT | 5 | 209 | 0.0005491 | 0.005473 |
468 | POSITIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 3 | 50 | 0.0005502 | 0.005473 |
469 | REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 4 | 118 | 0.0005568 | 0.005524 |
470 | POSITIVE REGULATION OF PROTEIN SECRETION | 5 | 211 | 0.0005733 | 0.005676 |
471 | GLUCOSE METABOLIC PROCESS | 4 | 119 | 0.0005748 | 0.005678 |
472 | NEGATIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 3 | 51 | 0.0005832 | 0.00575 |
473 | CYTOKINE PRODUCTION | 4 | 120 | 0.0005932 | 0.005835 |
474 | REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 4 | 122 | 0.0006312 | 0.006197 |
475 | NEGATIVE REGULATION OF PROTEOLYSIS | 6 | 329 | 0.0006364 | 0.006218 |
476 | POSITIVE REGULATION OF HOMEOSTATIC PROCESS | 5 | 216 | 0.0006374 | 0.006218 |
477 | NEGATIVE REGULATION OF TRANSPORT | 7 | 458 | 0.0006356 | 0.006218 |
478 | REGULATION OF NITRIC OXIDE BIOSYNTHETIC PROCESS | 3 | 53 | 0.0006531 | 0.006266 |
479 | REGULATION OF ENDOTHELIAL CELL DEVELOPMENT | 2 | 12 | 0.0006517 | 0.006266 |
480 | NEGATIVE REGULATION OF AUTOPHAGY | 3 | 53 | 0.0006531 | 0.006266 |
481 | REGULATION OF CHEMOKINE BIOSYNTHETIC PROCESS | 2 | 12 | 0.0006517 | 0.006266 |
482 | REGULATION OF ESTABLISHMENT OF ENDOTHELIAL BARRIER | 2 | 12 | 0.0006517 | 0.006266 |
483 | REGULATION OF PROTEIN COMPLEX DISASSEMBLY | 5 | 217 | 0.0006509 | 0.006266 |
484 | T CELL DIFFERENTIATION | 4 | 123 | 0.0006509 | 0.006266 |
485 | POSITIVE REGULATION OF INTERLEUKIN 2 BIOSYNTHETIC PROCESS | 2 | 12 | 0.0006517 | 0.006266 |
486 | MACROMOLECULE CATABOLIC PROCESS | 10 | 926 | 0.0006726 | 0.00644 |
487 | NEGATIVE REGULATION OF REPRODUCTIVE PROCESS | 3 | 54 | 0.00069 | 0.006579 |
488 | REGULATION OF MITOCHONDRIAL MEMBRANE POTENTIAL | 3 | 54 | 0.00069 | 0.006579 |
489 | RESPONSE TO UV | 4 | 126 | 0.0007125 | 0.00678 |
490 | REGULATION OF MITOTIC CELL CYCLE | 7 | 468 | 0.0007218 | 0.006855 |
491 | REGULATION OF B CELL PROLIFERATION | 3 | 55 | 0.0007281 | 0.0069 |
492 | REGULATION OF LIPID BIOSYNTHETIC PROCESS | 4 | 128 | 0.0007558 | 0.007133 |
493 | REGULATION OF DNA METABOLIC PROCESS | 6 | 340 | 0.0007556 | 0.007133 |
494 | POSITIVE REGULATION OF STEROID BIOSYNTHETIC PROCESS | 2 | 13 | 0.0007686 | 0.007181 |
495 | REGULATION OF HISTONE PHOSPHORYLATION | 2 | 13 | 0.0007686 | 0.007181 |
496 | REGULATION OF PROTEIN POLYUBIQUITINATION | 2 | 13 | 0.0007686 | 0.007181 |
497 | POSITIVE REGULATION OF MACROPHAGE DIFFERENTIATION | 2 | 13 | 0.0007686 | 0.007181 |
498 | REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY | 2 | 13 | 0.0007686 | 0.007181 |
499 | INNATE IMMUNE RESPONSE | 8 | 619 | 0.0007738 | 0.007215 |
500 | POSITIVE REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS | 3 | 58 | 0.0008505 | 0.007915 |
501 | REGULATION OF FIBROBLAST APOPTOTIC PROCESS | 2 | 14 | 0.0008949 | 0.008278 |
502 | INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 2 | 14 | 0.0008949 | 0.008278 |
503 | T CELL MIGRATION | 2 | 14 | 0.0008949 | 0.008278 |
504 | POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 4 | 135 | 0.000922 | 0.008512 |
505 | POSITIVE REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 3 | 60 | 0.000939 | 0.008652 |
506 | RESPONSE TO ETHANOL | 4 | 136 | 0.0009477 | 0.008697 |
507 | NEGATIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 4 | 136 | 0.0009477 | 0.008697 |
508 | REGULATION OF INTERLEUKIN 8 PRODUCTION | 3 | 61 | 0.0009853 | 0.009025 |
509 | MAINTENANCE OF LOCATION | 4 | 138 | 0.001001 | 0.009146 |
510 | REGULATION OF HEAT GENERATION | 2 | 15 | 0.00103 | 0.009274 |
511 | RESPIRATORY BURST | 2 | 15 | 0.00103 | 0.009274 |
512 | LIPID METABOLIC PROCESS | 11 | 1158 | 0.001025 | 0.009274 |
513 | NEGATIVE REGULATION OF INTERLEUKIN 12 PRODUCTION | 2 | 15 | 0.00103 | 0.009274 |
514 | NEGATIVE REGULATION OF B CELL PROLIFERATION | 2 | 15 | 0.00103 | 0.009274 |
515 | CHRONIC INFLAMMATORY RESPONSE | 2 | 15 | 0.00103 | 0.009274 |
516 | POSITIVE REGULATION OF MEMBRANE PROTEIN ECTODOMAIN PROTEOLYSIS | 2 | 15 | 0.00103 | 0.009274 |
517 | REGULATION OF VIRAL INDUCED CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 2 | 15 | 0.00103 | 0.009274 |
518 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 7 | 498 | 0.001038 | 0.00932 |
519 | POSITIVE REGULATION OF JUN KINASE ACTIVITY | 3 | 63 | 0.001082 | 0.009702 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | KINASE ACTIVITY | 22 | 842 | 6.222e-15 | 5.781e-12 |
2 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 22 | 992 | 1.747e-13 | 8.113e-11 |
3 | ENZYME BINDING | 27 | 1737 | 6.475e-13 | 2.005e-10 |
4 | X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 8 | 43 | 9.277e-13 | 2.031e-10 |
5 | PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 9 | 70 | 1.093e-12 | 2.031e-10 |
6 | TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY BINDING | 8 | 47 | 1.992e-12 | 3.084e-10 |
7 | CYTOKINE RECEPTOR BINDING | 13 | 271 | 2.763e-12 | 3.668e-10 |
8 | PHOSPHATIDYLINOSITOL KINASE ACTIVITY | 8 | 51 | 3.993e-12 | 4.637e-10 |
9 | DEATH RECEPTOR BINDING | 6 | 18 | 1.521e-11 | 1.57e-09 |
10 | UBIQUITIN LIKE PROTEIN LIGASE BINDING | 12 | 264 | 3.894e-11 | 3.617e-09 |
11 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 14 | 445 | 1.032e-10 | 8.719e-09 |
12 | PROTEIN KINASE ACTIVITY | 16 | 640 | 1.177e-10 | 9.115e-09 |
13 | KINASE REGULATOR ACTIVITY | 10 | 186 | 3.723e-10 | 2.66e-08 |
14 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 5 | 15 | 8.382e-10 | 5.562e-08 |
15 | PROTEIN HETERODIMERIZATION ACTIVITY | 13 | 468 | 2.369e-09 | 1.467e-07 |
16 | MOLECULAR FUNCTION REGULATOR | 20 | 1353 | 3.888e-09 | 2.212e-07 |
17 | CYSTEINE TYPE ENDOPEPTIDASE REGULATOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 6 | 42 | 4.048e-09 | 2.212e-07 |
18 | ADENYL NUCLEOTIDE BINDING | 21 | 1514 | 4.373e-09 | 2.257e-07 |
19 | ENZYME REGULATOR ACTIVITY | 17 | 959 | 5.331e-09 | 2.607e-07 |
20 | PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 5 | 30 | 3.833e-08 | 1.781e-06 |
21 | PROTEASE BINDING | 7 | 104 | 4.082e-08 | 1.806e-06 |
22 | PROTEIN KINASE A CATALYTIC SUBUNIT BINDING | 4 | 15 | 1.267e-07 | 5.352e-06 |
23 | INTERLEUKIN 1 RECEPTOR BINDING | 4 | 16 | 1.686e-07 | 6.264e-06 |
24 | RIBONUCLEOTIDE BINDING | 21 | 1860 | 1.573e-07 | 6.264e-06 |
25 | PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY | 4 | 16 | 1.686e-07 | 6.264e-06 |
26 | PROTEIN KINASE A BINDING | 5 | 42 | 2.222e-07 | 7.938e-06 |
27 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 6 | 86 | 3.252e-07 | 1.119e-05 |
28 | PROTEIN DIMERIZATION ACTIVITY | 16 | 1149 | 4.53e-07 | 1.503e-05 |
29 | CAMP BINDING | 4 | 23 | 8.065e-07 | 2.584e-05 |
30 | DEATH RECEPTOR ACTIVITY | 4 | 24 | 9.655e-07 | 2.99e-05 |
31 | PROTEIN PHOSPHATASE BINDING | 6 | 120 | 2.322e-06 | 6.958e-05 |
32 | TUMOR NECROSIS FACTOR RECEPTOR BINDING | 4 | 30 | 2.455e-06 | 7.126e-05 |
33 | RECEPTOR BINDING | 17 | 1476 | 2.56e-06 | 7.208e-05 |
34 | KINASE BINDING | 11 | 606 | 3.124e-06 | 8.536e-05 |
35 | IDENTICAL PROTEIN BINDING | 15 | 1209 | 4.655e-06 | 0.0001236 |
36 | CYCLIC NUCLEOTIDE BINDING | 4 | 36 | 5.2e-06 | 0.0001306 |
37 | INSULIN RECEPTOR SUBSTRATE BINDING | 3 | 11 | 5.063e-06 | 0.0001306 |
38 | KINASE INHIBITOR ACTIVITY | 5 | 89 | 9.658e-06 | 0.0002361 |
39 | PHOSPHATASE BINDING | 6 | 162 | 1.309e-05 | 0.0003118 |
40 | CYSTEINE TYPE PEPTIDASE ACTIVITY | 6 | 184 | 2.691e-05 | 0.0006098 |
41 | ENZYME INHIBITOR ACTIVITY | 8 | 378 | 2.658e-05 | 0.0006098 |
42 | PEPTIDASE ACTIVATOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 3 | 21 | 3.989e-05 | 0.0008823 |
43 | PROTEIN SERINE THREONINE PHOSPHATASE ACTIVITY | 4 | 64 | 5.245e-05 | 0.001116 |
44 | CYSTEINE TYPE ENDOPEPTIDASE INHIBITOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 3 | 23 | 5.287e-05 | 0.001116 |
45 | GROWTH FACTOR RECEPTOR BINDING | 5 | 129 | 5.805e-05 | 0.001198 |
46 | PEPTIDASE REGULATOR ACTIVITY | 6 | 214 | 6.254e-05 | 0.001263 |
47 | PROTEIN DOMAIN SPECIFIC BINDING | 9 | 624 | 0.0001575 | 0.003113 |
48 | HEAT SHOCK PROTEIN BINDING | 4 | 89 | 0.0001899 | 0.0036 |
49 | CYTOKINE RECEPTOR ACTIVITY | 4 | 89 | 0.0001899 | 0.0036 |
50 | PEPTIDASE ACTIVATOR ACTIVITY | 3 | 38 | 0.0002434 | 0.004522 |
51 | PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 5 | 178 | 0.0002632 | 0.004794 |
52 | SIGNAL TRANSDUCER ACTIVITY | 15 | 1731 | 0.0002935 | 0.005243 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 16 | 237 | 2.679e-17 | 1.565e-14 |
2 | PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX | 8 | 20 | 8.535e-16 | 2.492e-13 |
3 | CATALYTIC COMPLEX | 24 | 1038 | 3.851e-15 | 7.496e-13 |
4 | MEMBRANE MICRODOMAIN | 14 | 288 | 3.02e-13 | 4.409e-11 |
5 | MEMBRANE PROTEIN COMPLEX | 20 | 1020 | 2.723e-11 | 3.18e-09 |
6 | CILIARY BASE | 6 | 23 | 8.168e-11 | 7.95e-09 |
7 | TRANSFERASE COMPLEX | 16 | 703 | 4.647e-10 | 3.393e-08 |
8 | PROTEIN KINASE COMPLEX | 8 | 90 | 4.41e-10 | 3.393e-08 |
9 | EXTRINSIC COMPONENT OF MEMBRANE | 8 | 252 | 1.369e-06 | 8.881e-05 |
10 | PLASMA MEMBRANE PROTEIN COMPLEX | 10 | 510 | 4.689e-06 | 0.0002738 |
11 | CYTOSOLIC PART | 7 | 223 | 7.062e-06 | 0.0003749 |
12 | MEMBRANE REGION | 14 | 1134 | 1.089e-05 | 0.0005302 |
13 | PHOSPHATASE COMPLEX | 4 | 48 | 1.669e-05 | 0.0007498 |
14 | CILIARY PART | 7 | 307 | 5.508e-05 | 0.002298 |
15 | MICROTUBULE CYTOSKELETON | 12 | 1068 | 0.0001262 | 0.004913 |
16 | MITOCHONDRION | 15 | 1633 | 0.000155 | 0.005657 |
17 | PLASMA MEMBRANE RAFT | 4 | 86 | 0.0001663 | 0.005713 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | hsa04210_Apoptosis | 64 | 89 | 6.382e-165 | 1.13e-162 | |
2 | hsa04380_Osteoclast_differentiation | 22 | 128 | 5.264e-33 | 4.659e-31 | |
3 | hsa04660_T_cell_receptor_signaling_pathway | 21 | 108 | 1.041e-32 | 6.14e-31 | |
4 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 22 | 136 | 2.215e-32 | 9.801e-31 | |
5 | hsa04662_B_cell_receptor_signaling_pathway | 19 | 75 | 5.191e-32 | 1.838e-30 | |
6 | hsa04620_Toll.like_receptor_signaling_pathway | 20 | 102 | 3.215e-31 | 9.485e-30 | |
7 | hsa04722_Neurotrophin_signaling_pathway | 19 | 127 | 3.026e-27 | 7.651e-26 | |
8 | hsa04370_VEGF_signaling_pathway | 16 | 76 | 1.483e-25 | 3.282e-24 | |
9 | hsa04910_Insulin_signaling_pathway | 17 | 138 | 6.915e-23 | 1.36e-21 | |
10 | hsa04010_MAPK_signaling_pathway | 20 | 268 | 1.977e-22 | 3.499e-21 | |
11 | hsa04062_Chemokine_signaling_pathway | 16 | 189 | 6.985e-19 | 1.124e-17 | |
12 | hsa04510_Focal_adhesion | 16 | 200 | 1.747e-18 | 2.578e-17 | |
13 | hsa04914_Progesterone.mediated_oocyte_maturation | 12 | 87 | 5.706e-17 | 7.768e-16 | |
14 | hsa04973_Carbohydrate_digestion_and_absorption | 10 | 44 | 1.228e-16 | 1.552e-15 | |
15 | hsa04150_mTOR_signaling_pathway | 10 | 52 | 7.676e-16 | 9.057e-15 | |
16 | hsa04664_Fc_epsilon_RI_signaling_pathway | 11 | 79 | 1.113e-15 | 1.231e-14 | |
17 | hsa04630_Jak.STAT_signaling_pathway | 13 | 155 | 2.041e-15 | 2.125e-14 | |
18 | hsa04621_NOD.like_receptor_signaling_pathway | 10 | 59 | 2.996e-15 | 2.946e-14 | |
19 | hsa04012_ErbB_signaling_pathway | 11 | 87 | 3.382e-15 | 3.151e-14 | |
20 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 10 | 95 | 4.41e-13 | 3.903e-12 | |
21 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 8 | 42 | 7.57e-13 | 6.38e-12 | |
22 | hsa04115_p53_signaling_pathway | 8 | 69 | 5.013e-11 | 4.033e-10 | |
23 | hsa04622_RIG.I.like_receptor_signaling_pathway | 8 | 71 | 6.347e-11 | 4.885e-10 | |
24 | hsa04070_Phosphatidylinositol_signaling_system | 8 | 78 | 1.375e-10 | 1.014e-09 | |
25 | hsa04920_Adipocytokine_signaling_pathway | 7 | 68 | 2.038e-09 | 1.443e-08 | |
26 | hsa04720_Long.term_potentiation | 7 | 70 | 2.508e-09 | 1.707e-08 | |
27 | hsa04670_Leukocyte_transendothelial_migration | 8 | 117 | 3.627e-09 | 2.378e-08 | |
28 | hsa04623_Cytosolic_DNA.sensing_pathway | 6 | 56 | 2.42e-08 | 1.53e-07 | |
29 | hsa04114_Oocyte_meiosis | 7 | 114 | 7.712e-08 | 4.707e-07 | |
30 | hsa04810_Regulation_of_actin_cytoskeleton | 8 | 214 | 3.989e-07 | 2.354e-06 | |
31 | hsa04310_Wnt_signaling_pathway | 7 | 151 | 5.27e-07 | 3.009e-06 | |
32 | hsa04020_Calcium_signaling_pathway | 7 | 177 | 1.533e-06 | 8.482e-06 | |
33 | hsa04640_Hematopoietic_cell_lineage | 5 | 88 | 9.138e-06 | 4.901e-05 | |
34 | hsa00562_Inositol_phosphate_metabolism | 4 | 57 | 3.316e-05 | 0.0001726 | |
35 | hsa04360_Axon_guidance | 5 | 130 | 6.023e-05 | 0.0003046 | |
36 | hsa04962_Vasopressin.regulated_water_reabsorption | 2 | 44 | 0.008746 | 0.043 | |
37 | hsa04120_Ubiquitin_mediated_proteolysis | 3 | 139 | 0.01005 | 0.04807 | |
38 | hsa04742_Taste_transduction | 2 | 52 | 0.01206 | 0.05617 | |
39 | hsa04340_Hedgehog_signaling_pathway | 2 | 56 | 0.01389 | 0.06305 | |
40 | hsa04976_Bile_secretion | 2 | 71 | 0.02174 | 0.0962 | |
41 | hsa04971_Gastric_acid_secretion | 2 | 74 | 0.02349 | 0.1014 | |
42 | hsa04970_Salivary_secretion | 2 | 89 | 0.03303 | 0.1388 | |
43 | hsa04540_Gap_junction | 2 | 90 | 0.03371 | 0.1388 | |
44 | hsa04912_GnRH_signaling_pathway | 2 | 101 | 0.04157 | 0.1635 | |
45 | hsa04916_Melanogenesis | 2 | 101 | 0.04157 | 0.1635 | |
46 | hsa04270_Vascular_smooth_muscle_contraction | 2 | 116 | 0.05327 | 0.205 | |
47 | hsa04530_Tight_junction | 2 | 133 | 0.06775 | 0.2551 | |
48 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 2 | 168 | 0.101 | 0.3723 | |
49 | hsa04740_Olfactory_transduction | 2 | 388 | 0.3533 | 1 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | CECR7 |
hsa-miR-130b-5p;hsa-miR-17-3p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-197-3p;hsa-miR-215-5p;hsa-miR-24-3p;hsa-miR-26b-5p;hsa-miR-335-3p;hsa-miR-361-5p;hsa-miR-491-5p;hsa-miR-590-3p | 12 | IL1R1 | Sponge network | 0.551 | 0.56177 | 0.097 | 0.93138 | 0.556 |
2 | EMX2OS |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-1275;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-32-3p;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-362-3p;hsa-miR-374b-5p;hsa-miR-421;hsa-miR-424-5p;hsa-miR-501-3p;hsa-miR-502-3p;hsa-miR-502-5p;hsa-miR-505-3p;hsa-miR-548o-3p;hsa-miR-577;hsa-miR-663b;hsa-miR-93-5p | 27 | AKT3 | Sponge network | 1.057 | 0.31716 | 0.457 | 0.53933 | 0.542 |
3 | EMX2OS |
hsa-miR-130b-5p;hsa-miR-17-3p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-197-3p;hsa-miR-215-5p;hsa-miR-24-3p;hsa-miR-26b-5p;hsa-miR-30d-3p;hsa-miR-30e-3p;hsa-miR-335-3p;hsa-miR-548o-3p;hsa-miR-590-3p | 13 | IL1R1 | Sponge network | 1.057 | 0.31716 | 0.097 | 0.93138 | 0.517 |
4 | CECR7 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-1275;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-28-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-32-3p;hsa-miR-320a;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-362-3p;hsa-miR-362-5p;hsa-miR-501-3p;hsa-miR-502-3p;hsa-miR-502-5p;hsa-miR-93-5p | 22 | AKT3 | Sponge network | 0.551 | 0.56177 | 0.457 | 0.53933 | 0.508 |
5 | MIAT |
hsa-miR-153-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-20a-3p;hsa-miR-20a-5p;hsa-miR-224-5p;hsa-miR-24-2-5p;hsa-miR-29a-3p;hsa-miR-33a-5p;hsa-miR-452-5p | 10 | BCL2 | Sponge network | -0.118 | 0.86338 | -0.872 | 0.24496 | 0.452 |
6 | CECR7 |
hsa-miR-141-3p;hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-186-5p;hsa-miR-188-5p;hsa-miR-200a-3p;hsa-miR-20a-3p;hsa-miR-25-3p;hsa-miR-320a;hsa-miR-335-3p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-361-5p;hsa-miR-376a-5p;hsa-miR-429;hsa-miR-582-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-7-1-3p | 22 | IRAK3 | Sponge network | 0.551 | 0.56177 | 0.129 | 0.83349 | 0.45 |
7 | EMX2OS |
hsa-miR-141-3p;hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-186-5p;hsa-miR-188-5p;hsa-miR-200a-3p;hsa-miR-20a-3p;hsa-miR-224-3p;hsa-miR-25-3p;hsa-miR-32-5p;hsa-miR-324-5p;hsa-miR-335-3p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-374a-3p;hsa-miR-374b-5p;hsa-miR-421;hsa-miR-452-3p;hsa-miR-505-3p;hsa-miR-577;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-660-5p;hsa-miR-7-1-3p;hsa-miR-92a-3p | 27 | IRAK3 | Sponge network | 1.057 | 0.31716 | 0.129 | 0.83349 | 0.42 |
8 | MEG3 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-32-3p;hsa-miR-320c;hsa-miR-335-3p;hsa-miR-362-5p;hsa-miR-577;hsa-miR-663b;hsa-miR-93-5p | 18 | AKT3 | Sponge network | 0.433 | 0.33816 | 0.457 | 0.53933 | 0.405 |
9 | CECR7 |
hsa-let-7f-1-3p;hsa-miR-148a-5p;hsa-miR-148b-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-200b-3p;hsa-miR-29b-1-5p;hsa-miR-32-3p;hsa-miR-320a;hsa-miR-335-3p;hsa-miR-335-5p;hsa-miR-582-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-7-1-3p | 16 | PIK3CA | Sponge network | 0.551 | 0.56177 | 0.023 | 0.97942 | 0.368 |
10 | CECR7 |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-186-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-335-3p;hsa-miR-361-5p;hsa-miR-362-3p;hsa-miR-429;hsa-miR-452-5p;hsa-miR-590-3p | 11 | PRKAR2B | Sponge network | 0.551 | 0.56177 | -0.108 | 0.86421 | 0.346 |
11 | ZNF883 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-181b-5p;hsa-miR-20a-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-320a;hsa-miR-320c;hsa-miR-335-3p;hsa-miR-33a-3p | 13 | AKT3 | Sponge network | 0.913 | 0.16772 | 0.457 | 0.53933 | 0.3 |
12 | EMX2OS |
hsa-miR-1296-5p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-215-5p;hsa-miR-25-3p;hsa-miR-32-3p;hsa-miR-324-3p;hsa-miR-577;hsa-miR-590-3p | 13 | PRKAR1A | Sponge network | 1.057 | 0.31716 | 0.006 | 0.99718 | 0.293 |
13 | MEG3 |
hsa-miR-141-3p;hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-186-5p;hsa-miR-200a-3p;hsa-miR-20a-3p;hsa-miR-25-3p;hsa-miR-335-3p;hsa-miR-429;hsa-miR-577;hsa-miR-590-5p;hsa-miR-7-1-3p | 14 | IRAK3 | Sponge network | 0.433 | 0.33816 | 0.129 | 0.83349 | 0.279 |
14 | EMX2OS |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-186-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-32-5p;hsa-miR-335-3p;hsa-miR-362-3p;hsa-miR-452-5p;hsa-miR-590-3p;hsa-miR-92a-3p | 11 | PRKAR2B | Sponge network | 1.057 | 0.31716 | -0.108 | 0.86421 | 0.278 |
15 | ZNF883 |
hsa-miR-130b-5p;hsa-miR-17-3p;hsa-miR-181b-5p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-197-3p;hsa-miR-215-5p;hsa-miR-26b-5p;hsa-miR-30d-3p;hsa-miR-30e-3p;hsa-miR-335-3p | 11 | IL1R1 | Sponge network | 0.913 | 0.16772 | 0.097 | 0.93138 | 0.277 |
16 | EMX2OS |
hsa-let-7f-1-3p;hsa-miR-146a-5p;hsa-miR-148a-5p;hsa-miR-148b-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-200b-3p;hsa-miR-29b-1-5p;hsa-miR-32-3p;hsa-miR-335-3p;hsa-miR-335-5p;hsa-miR-339-5p;hsa-miR-374b-5p;hsa-miR-576-5p;hsa-miR-577;hsa-miR-582-3p;hsa-miR-590-3p;hsa-miR-7-1-3p | 19 | PIK3CA | Sponge network | 1.057 | 0.31716 | 0.023 | 0.97942 | 0.254 |